<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ketamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ketamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ketamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11499" href="/d/html/11499.html" rel="external">see "Ketamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13398" href="/d/html/13398.html" rel="external">see "Ketamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45497290"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ketalar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867292"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ketalar</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F185763"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant;</li>
<li>
                        General Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F185729"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> To decrease risk of respiratory depression and apnea, administer IV bolus doses over &gt;30 to 60 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70cf49d0-92bf-4407-8921-ee294d74d89b">Agitation, acute/severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation, acute/severe or refractory (adjunct) (off-label use): Note:</b> May be used when benzodiazepines and/or antipsychotics have failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29033344','lexi-content-ref-29136301','lexi-content-ref-Moore.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29033344','lexi-content-ref-29136301','lexi-content-ref-Moore.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 1 to 2 mg/kg once over 30 to 60 seconds; if initial sedation is inadequate, may repeat dose once 5 to 10 minutes after the initial dose using 0.5 to 1 mg/kg; however, this is not common if using the upper end of the initial dose range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-31735659','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-31735659','lexi-content-ref-Roberts.2019'])">Ref</a></span>). Some experts use an initial dose of 0.5 to 1 mg/kg in the emergency department with concomitant sedatives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735659','lexi-content-ref-Moore.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735659','lexi-content-ref-Moore.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Initial: 4 to 6 mg/kg once; if initial sedation is inadequate, may repeat dose once 10 to 25 minutes after the initial dose using 2 to 3 mg/kg; however, this is not common if using the upper end of the initial dose range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-28335913','lexi-content-ref-29033344','lexi-content-ref-30402516','lexi-content-ref-26899459','lexi-content-ref-31735659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-28335913','lexi-content-ref-29033344','lexi-content-ref-30402516','lexi-content-ref-26899459','lexi-content-ref-31735659'])">Ref</a></span>). Some experts use an initial dose of 2 mg/kg in the emergency department with concomitant sedatives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735659','lexi-content-ref-31335216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735659','lexi-content-ref-31335216'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71bafc4-1603-42b7-9a63-44320b2abb90">Analgesia, subanesthetic dosing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia, subanesthetic dosing (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute pain:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Prior to use, consult with a pain specialist or service experienced with ketamine use in this setting. Optimal doses and regimens have not been identified; refer to institutional protocols. Recommendations provided below are examples of regimens. May be useful for moderately to severely painful procedures and conditions that do not respond optimally to standard analgesics (eg, postoperative, burn, trauma, sickle cell disease vaso-occlusive pain).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 0.25 to 0.5 mg/kg bolus (maximum bolus: 35 mg), followed by 0.05 to 0.25 mg/kg/<b>hour</b> continuous infusion in patients who need a longer duration of analgesia; titrate to pain goal and tolerability; usual dosing range: 0.05 to 1 mg/kg/<b>hour</b>; may need to use doses at the higher range in patients who are opioid-tolerant or with opioid-induced hyperalgesia; duration of infusion: 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379','lexi-content-ref-29870457','lexi-content-ref-23856095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379','lexi-content-ref-29870457','lexi-content-ref-23856095'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intranasal (off-label route):</b> 0.2 to 1 mg/kg by administering half dose in each nostril (using 100 mg/mL solution); if necessary, may repeat after 10 to 15 minutes with 0.25 to 0.5 mg/kg; titrate to pain goal and tolerability. Doses up to 40 mg may be reliably administered intranasally; for doses &gt;40 mg, part of the dose will be delivered to the oropharynx and ingested orally due to volume limitations, which may decrease effectiveness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24127709','lexi-content-ref-26346210','lexi-content-ref-27829367','lexi-content-ref-27006733','lexi-content-ref-29396996','lexi-content-ref-24712757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24127709','lexi-content-ref-26346210','lexi-content-ref-27829367','lexi-content-ref-27006733','lexi-content-ref-29396996','lexi-content-ref-24712757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic pain, intractable:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Prior to use, consult with a pain specialist or service experienced with ketamine use in this setting. Optimal regimens, doses, and duration have not been identified; refer to institutional protocols. Long-term safety, efficacy, and timing of repeated ketamine treatments are not well established. Recommendations provided below are examples of regimens. May be used in refractory chronic pain (eg, complex regional pain syndrome, end-stage illness, neuropathies). May need to use doses at the higher range in opioid-tolerant patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29870457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29870457'])">Ref</a></span>). Reduce baseline opioids by 25% to 50% when used concomitantly with ketamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV intermittent infusion:</b> Initial: 0.25 to 0.6 mg/kg (usual maximum dose: 60 mg) as a 4- to 6-hour infusion; titrate to pain goal and tolerability; repeat daily for up to 2 to 10 days as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29870458','lexi-content-ref-11027905','lexi-content-ref-17525784','lexi-content-ref-31082965','lexi-content-ref-26096492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29870458','lexi-content-ref-11027905','lexi-content-ref-17525784','lexi-content-ref-31082965','lexi-content-ref-26096492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV continuous infusion:</b> Initial: 0.05 to 0.15 mg/kg/hour for 1 day outpatient or for 2 to 5 days inpatient; titrate to pain goal and tolerability; usual dosing range: 0.02 to 1 mg/kg/hour (maximum dose: 30 mg/hour; not well established) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29870458','lexi-content-ref-27648345','lexi-content-ref-29764182','lexi-content-ref-31082965','lexi-content-ref-26096492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29870458','lexi-content-ref-27648345','lexi-content-ref-29764182','lexi-content-ref-31082965','lexi-content-ref-26096492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SubQ:</b> Initial: 0.1 to 0.6 mg/kg (usual 2.5 to 25 mg) as needed; titrate to pain goal and tolerability. In patients who need a longer duration of analgesia, follow with continuous SubQ infusion at 0.1 to 1.2 mg/kg/<b>hour</b> (maximum daily dose: 500 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29870458','lexi-content-ref-26096492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29870458','lexi-content-ref-26096492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: Note:</b> Used in refractory chronic pain (eg, advanced illness or palliative care) in a hospitalized patient when other regimens have failed.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 0.5 mg/kg/day administered in 3 to 4 divided doses as needed; then increase dose in increments of ~5 mg/<b>dose</b> based on pain goal and tolerability; maximum daily escalation dose: 15 to 20 mg; maximum dose: 800 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19879174','lexi-content-ref-29870458','lexi-content-ref-25381898','lexi-content-ref-27625475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19879174','lexi-content-ref-29870458','lexi-content-ref-25381898','lexi-content-ref-27625475'])">Ref</a></span>). <b>Note:</b> May administer dose as the undiluted injectable or mixed with an appropriate flavoring agent (eg, simple syrup).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8a51d52-12e3-4d5e-9287-c5cb1ed99cb7">Depressive episode associated with major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Depressive episode (severe, treatment resistant) associated with major depressive disorder (unipolar) (off-label use): Note:</b> Avoid or use with caution in patients with substance use disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.5 mg/kg administered over 40 minutes; may repeat at a frequency of 1 to 3 times weekly; may increase dose to 0.75 to 1 mg/kg based on response and tolerability. Treatment up to 6 weeks has been studied, although optimal duration of therapy is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30283029','lexi-content-ref-30922101','lexi-content-ref-28249076','lexi-content-ref-27056608','lexi-content-ref-Thase.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30283029','lexi-content-ref-30922101','lexi-content-ref-28249076','lexi-content-ref-27056608','lexi-content-ref-Thase.1'])">Ref</a></span>). In those who respond to short-term ketamine infusions (eg, 1 to 4 weeks), some experts recommend transitioning to maintenance treatment with antidepressants and/or psychotherapy instead of prolonged ketamine treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33174760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33174760'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d181a5f4-ff4e-4c53-9710-1ef232f62b7c">General anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Induction of anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Useful in hypotensive patients or patients likely to develop hypotension during induction; lower doses may be used if concomitant anesthesia/sedatives (eg, midazolam) are administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1','lexi-content-ref-Gropper.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1','lexi-content-ref-Gropper.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 0.5 to 2 mg/kg <b>or</b> 0.5 to 1 mg/kg in patients with shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1','lexi-content-ref-Gropper.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1','lexi-content-ref-Gropper.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM</b> (use only if IV access is not available): 4 to 6 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1','lexi-content-ref-Gropper.2019','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1','lexi-content-ref-Gropper.2019','lexi-content-ref-Roberts.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of anesthesia (adjunct with total intravenous anesthesia): </b>
<b>Note:</b> Adjunct to reduce requirements of other anesthetic agents. Typically reserved for opioid-tolerant patients in order to avoid or limit opioid requirements (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khorsand.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khorsand.1'])">Ref</a></span>); concurrent use of nitrous oxide reduces ketamine requirements (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gropper.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gropper.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 0.25 to 0.35 mg/kg, followed by continuous infusion up to 1 mg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khorsand.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khorsand.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ae6a1f4-4e96-4145-8087-a2a319403cc5">Mechanically ventilated patients in the ICU, analgesia/sedation/agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanically ventilated patients in the ICU, analgesia/sedation/agitation (adjunct or alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used as part of a multimodal strategy and adjunct for the reduction of opioid and sedative requirements and/or for the management of opioid-induced hyperalgesia in patients with acute/chronic pain or postsurgical pain. Pain should be monitored using validated scales (eg, behavioral pain scale, critical-care pain observation tool) in patients who are unable to self-report. If used for sedation, titrate to a light level of sedation (eg, Richmond Agitation Sedation Scale 0 to −2), unless deeper sedation is clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>). Refer to institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.1 to 0.5 mg/kg bolus, followed by a 0.2 to 0.5 mg/kg/<b>hour</b> continuous infusion; titrate dose to pain and/or sedation goal (dosing range: 0.04 to 2.5 mg/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28468568','lexi-content-ref-30746728','lexi-content-ref-29193185','lexi-content-ref-23269131','lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28468568','lexi-content-ref-30746728','lexi-content-ref-29193185','lexi-content-ref-23269131','lexi-content-ref-30113379'])">Ref</a></span>). <b>Note:</b> Higher initial bolus doses (eg, 1 to 2 mg/kg) can be used to manage severely agitated patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-29033344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-29033344'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e957755b-7e6a-4c47-abc7-399e245a30c5">Procedural sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation (off-label use): Note:</b> Although rarely needed, may consider using midazolam to decrease risk <b>or </b>to treat emergence reactions. However, premedication may significantly prolong recovery time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-30611640','lexi-content-ref-10730829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-30611640','lexi-content-ref-10730829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 1 to 2 mg/kg over 1 to 2 minutes; if initial sedation is inadequate or for longer procedures, repeat dose (0.5 to 1 mg/kg) every 5 to 10 minutes; use lower doses (0.25 to 0.5 mg/kg) depending on concomitant sedation and clinical status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-10730829','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-10730829','lexi-content-ref-Roberts.2019'])">Ref</a></span>). Alternatively, may consider an initial dose of 0.375 to 0.75 mg/kg when combined with propofol (as a 1:1 mixture); repeat with ~0.188 to 0.375 mg/kg, as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24438649','lexi-content-ref-22401952','lexi-content-ref-27460905','lexi-content-ref-36042988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24438649','lexi-content-ref-22401952','lexi-content-ref-27460905','lexi-content-ref-36042988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM: Note:</b> Onset of sedation will be delayed ~5 minutes with this route.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 4 to 5 mg/kg as a single dose; if sedation is inadequate after 5 to 10 minutes, repeat dose (2 to 5 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-Roberts.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b90e6d7-ef99-4a0d-b70e-5c9f62cb6a8f">Rapid sequence intubation outside the operating room, induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation outside the operating room, induction (off-label use): Note:</b> Consider in patients with bronchospasm and/or hemodynamic compromise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roberts.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 1 to 2 mg/kg once over 1 minute; in patients with shock, reduce initial dose by half (eg, 0.5 to 1 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19573904','lexi-content-ref-31123547','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635','lexi-content-ref-27993308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19573904','lexi-content-ref-31123547','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635','lexi-content-ref-27993308'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraosseous </b>(use only if IV access is not available)<b>:</b> Initial: 100 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24963149','lexi-content-ref-28979485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24963149','lexi-content-ref-28979485'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3cf4716-2d40-4dd4-9822-7d4ea864180d">Status epilepticus, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus, refractory (off-label use): Note:</b> Used as an alternative or adjunct to midazolam, propofol, or barbiturates after conventional intermittent antiseizure therapies have failed. Mechanical ventilation and hemodynamic support generally required; continuous EEG is recommended; titrate doses to cessation of electrographic seizures or burst suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-30993550','lexi-content-ref-29922905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-30993550','lexi-content-ref-29922905'])">Ref</a></span>). Optimal regimen and dose are uncertain; refer to institutional protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Loading dose:</b> Initial: 1.5 mg/kg <b>or</b> 0.5 to 3 mg/kg; repeat loading dose of 0.5 mg/kg every 3 to 5 minutes as needed for electrographic/burst suppression, followed by continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b> After initial loading dose and electrographic suppression, begin at a rate of 0.1 to 4 mg/kg/hour; titrate as needed for electrographic/burst suppression; maximum dose: 15 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23758557','lexi-content-ref-27544138','lexi-content-ref-30232735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23758557','lexi-content-ref-27544138','lexi-content-ref-30232735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Generally, a period of at least 24 hours of electrographic suppression is suggested prior to down-titrating the continuous infusion; withdraw gradually by decreasing the dose by 20% every 3 hours while continuing conventional antiseizure therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991384"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988568"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F56715143"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC<i>.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1 and 2 obesity (BMI 30 to 39 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM, Intranasal, Oral, SUBQ:</b> Use <b>actual body weight</b> for weight-based dosing, then titrate to clinical effect, if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.1'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 3 obesity (BMI ≥40 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM, Intranasal, Oral, SUBQ:</b> Use either <b>adjusted body weight</b> or <b>ideal body weight</b> for initial weight-based dose calculations, then titrate to clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32513237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32513237'])">Ref</a></span>). If rapid sedation or clinical effect is needed, use <b>adjusted body weight</b> for initial weight-based dose calculations, then titrate to clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.1'])">Ref</a></span>). Clinicians should <b>not</b> change dosing weight from one weight metric to another during therapy (ie, actual body weight to/from adjusted body weight or ideal body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.1'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b> Ketamine, a short-acting IV induction anesthetic, has a large V<sub>d</sub> (2.1 to 3.1 L/kg), with peak anesthetic effects occurring within minutes and a rapid loss of effect related to redistribution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7459184','lexi-content-ref-32513237','lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7459184','lexi-content-ref-32513237','lexi-content-ref-expert.1'])">Ref</a></span>). There are limited data on the influence of obesity on ketamine dosing or pharmacokinetics. A variety of studies have been performed in the past decade for acute pain and depression in patients with obesity or severe obesity using lean body weight, ideal body weight, and actual body weight; however, no consistency between dosing weight and clinical effect has been demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33120301','lexi-content-ref-33115424','lexi-content-ref-30095550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33120301','lexi-content-ref-33115424','lexi-content-ref-30095550'])">Ref</a></span>). This inconsistency (even within indication) in specific weights used for dosing limits definition of a universal weight-based dosing strategy. Due to ketamine's active metabolite, prolonged use may contribute to the risk of accumulation and toxicity, especially in patients with BMI ≥40 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32513237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32513237'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F185730"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F185746"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13398" href="/d/html/13398.html" rel="external">see "Ketamine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> The American College of Emergency Physicians considers the use of ketamine in infants &lt;3 months of age to be an absolute contraindication, due to the higher risk of airway complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Individualize dose and titrate to effect. May be used in combination with anticholinergic agents to decrease hypersalivation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56e217a5-d510-4005-bb1e-fe31e0f5e3ca">Analgesia, acute pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia, acute pain (low dose; sub-dissociative):</b> Very limited data available: Optimal dose not established: <b>Note:</b> Use of mucosal atomizer device is recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Intranasal: Usual: 1 mg/kg/dose, may repeat once; range: 0.5 to 1.5 mg/kg/dose; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32665505','lexi-content-ref-30592476','lexi-content-ref-25447557','lexi-content-ref-32739857','lexi-content-ref-28926159','lexi-content-ref-29287863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32665505','lexi-content-ref-30592476','lexi-content-ref-25447557','lexi-content-ref-32739857','lexi-content-ref-28926159','lexi-content-ref-29287863'])">Ref</a></span>). Dosing based on 2 double-blind, randomized, controlled studies (n=80 in ketamine treatment group, age range: 3 to 17 years) comparing intranasal ketamine to intranasal fentanyl in the treatment of acute pain due to isolated limb injury or suspected single extremity fracture in the emergency department; pain relief was similar between both treatment groups; no serious adverse effects were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25447557','lexi-content-ref-28926159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25447557','lexi-content-ref-28926159'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8fabc082-bd80-45c8-8172-1246c1df2bae">Anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pre-anesthetic sedation:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months: 3 mg/kg/dose (half dose per nostril) administered at least 15 minutes prior to mask induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9243683','lexi-content-ref-2215104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9243683','lexi-content-ref-2215104'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;2 years: 3 to 5 mg/kg/dose (half dose per nostril) administered at least 15 minutes prior to mask induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9243683','lexi-content-ref-18092436','lexi-content-ref-2215104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9243683','lexi-content-ref-18092436','lexi-content-ref-2215104'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 7 years: 3 to 6 mg/kg/dose (half dose per nostril) administered 15 to 40 minutes prior to induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9243683','lexi-content-ref-18092436','lexi-content-ref-2215104','lexi-content-ref-15675259','lexi-content-ref-8443849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9243683','lexi-content-ref-18092436','lexi-content-ref-2215104','lexi-content-ref-15675259','lexi-content-ref-8443849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Children ≤8 years: 6 to 8 mg/kg/dose 20 to 30 minutes prior to surgery. Dosing based on 2 prospective, randomized, double-blind, placebo-controlled, dose finding trials. The larger trial compared 4 mg/kg, 6 mg/kg, and 8 mg/kg (n=20 in each group; age range: 2 to 8 years) and found that patients who received 8 mg/kg were significantly more calm, but also had slightly longer recovery times. Sedation was effective within 10 minutes of administration in 80% and 45% of the patients in the 8 mg/kg and 6 mg/kg, groups respectively, but was not effective in the 4 mg/kg group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12553389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12553389'])">Ref</a></span>). The other study compared 3 mg/kg and 6 mg/kg (n=15 in each group, age range: 1 to 7 years) and found that patients who received 6 mg/kg had satisfactory sedation without prolonged recovery times, but the 3 mg/kg dose did not provide uniform sedation nor offer a significant improvement in premedicated emotional state compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1729932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1729932'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Rectal: Administer 15 to 45 minutes prior to surgery as a single agent; when used in combination with other sedatives, lower doses should be considered. Efficacy was reported in trials comparing rectal ketamine to rectal doses of other agents (fentanyl/droperidol, midazolam) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2215104','lexi-content-ref-11046209','lexi-content-ref-1890517','lexi-content-ref-20865876','lexi-content-ref-20157833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2215104','lexi-content-ref-11046209','lexi-content-ref-1890517','lexi-content-ref-20865876','lexi-content-ref-20157833'])">Ref</a></span>). Reported effective range:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 2 to 6 months: 8 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥7 months and Children ≤9 years: 8 to 10 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Although lower doses of 4 to 7 mg/kg/dose have been reported, they were less effective. In some patients, the 10 mg/kg/dose was associated with prolonged postoperative sedation. When used in combination with midazolam, a lower rectal dose of 3 mg/kg/dose has been effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1443705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1443705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction of anesthesia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months, Children, and Adolescents &lt;16 years: Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">IM: 5 to 10 mg/kg has been reported and suggested by experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2013','lexi-content-ref-15675923','lexi-content-ref-18544145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2013','lexi-content-ref-15675923','lexi-content-ref-18544145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 1 to 3 mg/kg has been reported and suggested by experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2013','lexi-content-ref-15675923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2013','lexi-content-ref-15675923'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">IM: 6.5 to 13 mg/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 1 to 4.5 mg/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance of anesthesia:</i> Adolescents ≥16 years: May administer supplemental doses of one-half to the full induction dose as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f15c5b6-101d-4fe3-81e9-4b33157081ff">Endotracheal intubation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal intubation:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 to 2 mg/kg as part of rapid sequence sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-23188232','lexi-content-ref-Fuhrman.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-23188232','lexi-content-ref-Fuhrman.2011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80fa9430-2443-4441-b8ad-c696f9ec247e">Sedation/analgesia, procedural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation/analgesia, procedural:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ketamine without propofol: </i>Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 4 to 5 mg/kg as a single dose; may give a repeat dose (range: 2 to 5 mg/kg) if sedation inadequate after 5 to 10 minutes or if additional doses are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>). Some have recommended smaller doses (2 to 2.5 mg/kg) for minor procedures (eg, wound suture with local anesthetic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15107365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15107365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 1 to 2 mg/kg over 30 to 60 seconds. If initial sedation inadequate or repeated doses are necessary to accomplish a longer procedure, may administer additional doses of 0.5 to 1 mg/kg every 5 to 15 minutes as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-23364373','lexi-content-ref-15006978','lexi-content-ref-20924617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-23364373','lexi-content-ref-15006978','lexi-content-ref-20924617'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal: <b>Note:</b> Use of mucosal atomizer device is recommended:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥3 months and Children: 3 to 6 mg/kg (half dose per nostril), doses up to 9 mg/kg have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2019','lexi-content-ref-29364490','lexi-content-ref-31290798','lexi-content-ref-28319161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2019','lexi-content-ref-29364490','lexi-content-ref-31290798','lexi-content-ref-28319161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Children and Adolescents: 5 mg/kg with oral midazolam given 30 to 45 minutes before the procedure. Dosing based on 2 prospective, randomized, blinded studies involving patients aged 1 to 10 years with either laceration repair or burn wound care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23686730','lexi-content-ref-23480923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23686730','lexi-content-ref-23480923'])">Ref</a></span>). A lower dose (3 mg/kg) in addition to midazolam was effective in a study comparing different routes (IV, oral, rectal) of ketamine plus midazolam for invasive procedures in oncology patients. The oral group included 24 patients (mean age: 3.9 ± 1.3 years); incidence of optimal sedation was similar between groups (75% for the oral group) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15357562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15357562'])">Ref</a></span>). <b>Note:</b> A higher dose (10 mg/kg) has been used successfully as monotherapy prior to procedures in pediatric oncology patients (n=35, age: 14 months to 17 years; mean age: 6.5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1408506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1408506'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Rectal: Children 1 to 8 years: 1.5 to 3 mg/kg with midazolam as a single dose 20 minutes prior to painful procedure. Dosing based on 2 studies. The first was completed in children with burns requiring dressing changes (n=47 procedures in 30 patients, mean age: 1.9 years, range: 10 months to 7.3 years). Patients received 0.75 mg/kg of the S(+) isomer (equivalent to 1.5 mg/kg of racemic ketamine) along with rectal midazolam 20 minutes prior to dressing changes; 94% of the procedures were reported to have good or excellent analgesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15343462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15343462'])">Ref</a></span>). The second study compared different routes (IV, oral, rectal) of ketamine plus midazolam for invasive procedures in oncology patients. The rectal group included 24 patients (mean age: 3.7 ± 1.1 years) who received 3 mg/kg of ketamine in addition to midazolam. Incidence of optimal sedation was similar between groups (79% for the rectal group) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15357562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15357562'])">Ref</a></span>). In both of these studies, rectal ketamine was well tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ketamine with propofol ("ketofol"):</i> Infants ≥3 months, Children, and Adolescents: IV: 0.5 to 0.75 mg/kg of each agent. This combination has been used to decrease the dose of each agent required. It has been proposed that these lower doses help decrease adverse effects, ketamine may decrease the propofol-related hypotension and respiratory depression, and propofol may decrease the ketamine associated nausea and emergence reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24438649','lexi-content-ref-23222112','lexi-content-ref-20947210','lexi-content-ref-17059854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24438649','lexi-content-ref-23222112','lexi-content-ref-20947210','lexi-content-ref-17059854'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19f0e82a-64e2-4557-940a-d9e6e706a194">Sedation/analgesia, critically ill patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation/analgesia, critically ill patients:</b> Very limited data available: Infants ≥5 months, Children, and Adolescents: Initial dose: IV: 0.5 to 2 mg/kg, then continuous IV infusion: 5 to 20 mcg/kg/minute (0.3 to 1.2 <b>mg</b>/kg/<b>hour</b>); start at lower dosage listed and titrate to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16567251','lexi-content-ref-3698618','lexi-content-ref-2379394','lexi-content-ref-6892475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16567251','lexi-content-ref-3698618','lexi-content-ref-2379394','lexi-content-ref-6892475'])">Ref</a></span>); doses as high as 60 mcg/kg/minute (3.6 <b>mg</b>/kg/<b>hour</b>) have been reported in patients with refractory bronchospasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8905436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8905436'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114927"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51114928"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56430798"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Airway complications</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When used for procedural sedation for major procedures involving the posterior pharynx (eg, endoscopy) or in patients with an active pulmonary infection or disease (including upper respiratory disease or asthma), the use of ketamine increases the risk of <b>laryngospasm </b>(rare and typically transient) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>). The manufacturer recommends against the use of ketamine alone in surgery or diagnostic procedures of the pharynx, larynx, or bronchial tree; mechanical stimulation of the pharynx should be avoided, whenever possible, if ketamine is used alone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; ketamine does not suppress pharyngeal and laryngeal reflexes. Laryngospasm may occur secondary to stimulation of the vocal cords by instrumentation and/or ketamine-induced increased salivary secretions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher IV doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19201064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19201064'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IM administration (and higher doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33000033','lexi-content-ref-24803768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33000033','lexi-content-ref-24803768'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients &lt;2 years or ≥13 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19201064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19201064'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Active pulmonary infection or disease, including upper respiratory disease or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of airway instability, tracheal surgery, or tracheal stenosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketamine causes <b>increased blood pressure</b>, <b>increased heart rate</b>, and increased cardiac output, thereby increasing myocardial oxygen demand; <b>cardiac arrhythmia</b>, cardiac decompensation, <b>decreased blood pressure</b>, and <b>decreased heart rate </b>have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19546251','lexi-content-ref-16703233','lexi-content-ref-2417535','lexi-content-ref-8602672','lexi-content-ref-Miller.2010','lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19546251','lexi-content-ref-16703233','lexi-content-ref-2417535','lexi-content-ref-8602672','lexi-content-ref-Miller.2010','lexi-content-ref-27400984'])">Ref</a></span>). In a scientific statement from the American Heart Association, ketamine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>). Resolution of increased blood pressure usually occurs within 15 minutes after the peak.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Ketamine has both central sympathetic stimulation and inhibition of catecholamine uptake and direct negative inotropic effects. Central sympathetic stimulation results in increased blood pressure, heart rate, cardiac output, and therefore, increased myocardial oxygen demand (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19546251','lexi-content-ref-Miller.2010','lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19546251','lexi-content-ref-Miller.2010','lexi-content-ref-27400984'])">Ref</a></span>). Direct negative inotropic effects may predominate in patients with heart failure and contribute to decompensation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16703233','lexi-content-ref-8602672','lexi-content-ref-Miller.2010','lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16703233','lexi-content-ref-8602672','lexi-content-ref-Miller.2010','lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; a peak in blood pressure occurs within a few minutes of administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known or suspected coronary artery disease, angina, hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults with risk factors for coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625','lexi-content-ref-27400984','lexi-content-ref-31488795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625','lexi-content-ref-27400984','lexi-content-ref-31488795'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Catecholamine depletion (hypotension) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27130803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27130803'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketamine may cause <b>drug dependence</b> (withdrawal symptoms on discontinuation) and <b>drug tolerance</b> with prolonged use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>). Multiple case reports of ketamine misuse have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16869851','lexi-content-ref-24813545','lexi-content-ref-25035566','lexi-content-ref-12762561','lexi-content-ref-26757313','lexi-content-ref-10402883','lexi-content-ref-12075653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16869851','lexi-content-ref-24813545','lexi-content-ref-25035566','lexi-content-ref-12762561','lexi-content-ref-26757313','lexi-content-ref-10402883','lexi-content-ref-12075653'])">Ref</a></span>). A <b>withdrawal syndrome </b>following discontinuation may include symptoms such as shaking, sweating, palpitations, fatigue, decreased appetite, chills, autonomic arousal, lacrimation, restlessness, cravings, dysphoria, anxiety, depressed mood, nightmares, paranoia, delusions, and hallucinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>). Typical duration of withdrawal symptoms is ~3 days, with some cases persisting for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; development of dependence may be related to the psychological effects of ketamine and tolerance. Ketamine is structurally similar to phencyclidine and the psychological effects contributing to dependence may include euphoria, perceptual changes, dissociation, and hallucinations. Tolerance most likely occurs due to auto-induction of metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826','lexi-content-ref-24149025','lexi-content-ref-Niesters.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826','lexi-content-ref-24149025','lexi-content-ref-Niesters.2013'])">Ref</a></span>). Dependence may also be related to N-methyl-D-aspartate (NMDA) glutamate receptor blockade, producing alcohol-like subjective effects, as well as opioid effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24813545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24813545'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Dependence: Delayed; from isolated case reports, dependence may evolve over weeks to years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16869851','lexi-content-ref-24813545','lexi-content-ref-25035566','lexi-content-ref-12762561','lexi-content-ref-26757313','lexi-content-ref-10402883','lexi-content-ref-12075653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16869851','lexi-content-ref-24813545','lexi-content-ref-25035566','lexi-content-ref-12762561','lexi-content-ref-26757313','lexi-content-ref-10402883','lexi-content-ref-12075653'])">Ref</a></span>). Withdrawal syndrome: Rapid; symptoms usually occur within 24 hours of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term high-dose use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16869851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16869851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12075653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12075653'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of multiple substance use disorders (eg, alcohol, cannabis, opioids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25035566','lexi-content-ref-12762561','lexi-content-ref-12075653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25035566','lexi-content-ref-12762561','lexi-content-ref-12075653'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ease of access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25035566','lexi-content-ref-10402883']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25035566','lexi-content-ref-10402883'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Emergence reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prolonged emergence from anesthesia</b>, which can manifest as vivid dreams, <b>hallucinations</b>, and/or frank <b>delirium</b> commonly occur in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17038218','lexi-content-ref-15765332','lexi-content-ref-21256625','lexi-content-ref-1308374','lexi-content-ref-26361209','lexi-content-ref-26096492','lexi-content-ref-6892475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17038218','lexi-content-ref-15765332','lexi-content-ref-21256625','lexi-content-ref-1308374','lexi-content-ref-26361209','lexi-content-ref-26096492','lexi-content-ref-6892475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may occur due to depression of auditory and visual relay nuclei, leading to misperception and/or misinterpretation of auditory and visual stimuli (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17038218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17038218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; emergence reactions may occur up to 24 hours postoperatively.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26361209','lexi-content-ref-6892475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26361209','lexi-content-ref-6892475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15765332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15765332'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;16 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6892475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6892475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6892475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6892475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive noise or stimulation during recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15765332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15765332'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• People who normally dream or have a history of a personality disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6892475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6892475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ketamine monotherapy (concurrent use with a benzodiazepine may reduce risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17038218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17038218'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Genitourinary effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lower urinary tract and bladder symptoms, including <b>dysuria</b>, <b>urinary frequency</b>, <b>urinary urgency</b>, <b>urinary incontinence</b>, <b>hematuria</b>, and <b>nocturia</b>, have been reported in patients with a history of chronic ketamine use or abuse and may be related to ketamine treatment, not the underlying condition. Additional findings from diagnostic studies have included <b>cystitis</b>, <b>hydronephrosis</b>, and <b>bladder dysfunction</b> (reduced capacity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23832948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23832948'])">Ref</a></span>). Reversibility of symptoms depends on time to diagnosis and intervention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24807773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24807773'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; several proposed mechanisms, including direct effects of ketamine and the active metabolite, norketamine/hydroxynorketamine on bladder mucosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22248834','lexi-content-ref-22710265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22248834','lexi-content-ref-22710265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; case reports range from 1 month to 4.5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22248834','lexi-content-ref-22710265','lexi-content-ref-24807773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22248834','lexi-content-ref-22710265','lexi-content-ref-24807773'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic use or abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23832948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23832948'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Frequency of use of other drugs (eg, opiates, methamphetamine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23474358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23474358'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female gender (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23474358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23474358'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of urinary tract infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23474358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23474358'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurodevelopmental effects in children</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Animal studies have shown that prolonged or repeated exposure to medications for anesthesia or sedation cause adverse effects on brain maturation resulting in changes in behavior and learning. Some human studies have also suggested similar effects, including epidemiological studies in humans that have observed various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and attention deficit hyperactivity disorder. However, data are limited, inconclusive, and further studies are needed to fully characterize findings. Based on the potential risk, the FDA warned in 2016 that in neonates, infants, children &lt;3 years, and patients in the third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis) undergoing repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures/critical illness, there may be detrimental effects on the child's or fetus’ brain development which may lead to various cognitive and behavioral problems. Relatively short exposure (&lt;3 hours) to sedatives or anesthetics during surgery or procedures is unlikely to adversely affect brain development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-30921252','lexi-content-ref-33509654','lexi-content-ref-28915132','lexi-content-ref-21507125','lexi-content-ref-9872743','lexi-content-ref-32426747','lexi-content-ref-23413121','lexi-content-ref-SPS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-30921252','lexi-content-ref-33509654','lexi-content-ref-28915132','lexi-content-ref-21507125','lexi-content-ref-9872743','lexi-content-ref-32426747','lexi-content-ref-23413121','lexi-content-ref-SPS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Mechanism: </i>Unknown; in juvenile animal studies, drugs that potentiate gamma-aminobutyric acid activity and/or block N-methyl-D aspartate receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates, infants, children &lt;3 years, and pregnant patients in their third trimester undergoing procedures lasting &gt;3 hours or multiple procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketamine may rarely cause <b>respiratory depression</b> or <b>apnea</b>, which are usually transient. These adverse reactions are most associated with rapid IV administration but have also been reported with IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27692755','lexi-content-ref-21256625','lexi-content-ref-19404223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27692755','lexi-content-ref-21256625','lexi-content-ref-19404223'])">Ref</a></span>). According to the manufacturer, overdose is also a risk factor for these adverse reactions; however, respiratory depression and apnea have been reported in the setting of slow sub-anesthetic IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33489089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33489089'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically, 1 to 2 minutes after IV administration or 4 to 5 minutes after IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>). In the case of respiratory depression and apnea in the setting of slow sub-clinical IV infusion, onset occurred 25 minutes after the start of ketamine infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33489089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33489089'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Overdose</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21256625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21256625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other CNS depressants (eg, benzodiazepines, opioids)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F185700"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Prolonged emergence from anesthesia (12%; includes agitation, confusion, delirium, dreamlike state, excitement, hallucinations, irrational behavior, vivid imagery)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, cardiac decompensation, decreased blood pressure, decreased heart rate, increased blood pressure, increased heart rate</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, morbilliform rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site, rash at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypertonia (tonic-clonic movements sometimes resembling seizures), psychiatric disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, increased intraocular pressure, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Airway obstruction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ventricular premature contractions (Cabbabe 1985)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Central diabetes insipidus (Hatab 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Biliary tract disease (dilation; Cotter 2021), cholangitis (Cotter 2021), sialorrhea (Hatab 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder dysfunction (reduced capacity) (Wei 2013), cystitis (including cystitis noninfective, cystitis interstitial, cystitis ulcerative, cystitis erosive, cystitis hemorrhagic) (Wei 2013), dysuria (Wei 2013), hematuria (Wei 2013), nocturia (Wei 2013), urinary frequency (Wei 2013), urinary incontinence (Wei 2013), urinary urgency (Wei 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatobiliary function (with recurrent or continuous use; including pericholeductal fibrosis) (Cotter 2021), hepatic cirrhosis (Cotter 2021), increased direct serum bilirubin (Cotter 2021), increased gamma-glutamyl transferase (Cotter 2021), increased liver enzymes (Cotter 2021), increased serum alanine aminotransferase (Cotter 2021), increased serum alkaline phosphatase (Cotter 2021), increased serum aspartate aminotransferase (Cotter 2021), increased serum bilirubin (Cotter 2021), jaundice (Cotter 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Chow 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug dependence (Pal 2002), increased cerebrospinal fluid pressure (List 1972), withdrawal syndrome (Cosci 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm (Green 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Hydronephrosis (Wei 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (Driver 2017; Gómez-Revuelta 2020), respiratory depression (Melendez 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug tolerance</p></div>
<div class="block coi drugH1Div" id="F185713"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ketamine or any component of the formulation; conditions in which an increase in blood pressure would be hazardous</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> When used for procedural sedation and analgesia in the emergency department, the following additional absolute contraindications according to the American College of Emergency Physicians have been asserted (ACEP [Green 2011]): Infants &lt;3 months of age; known or suspected schizophrenia (even if currently stable or controlled with medications)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of cerebrovascular accident; severe cardiac decompensation; surgery of the pharynx, larynx, or bronchial tree unless adequate muscle relaxants are used</p></div>
<div class="block war drugH1Div" id="F185697"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). When used for outpatient surgery, the patient should be accompanied by a responsible adult. Driving, operating hazardous machinery, or engaging in hazardous activities should not be undertaken for ≥24 hours after anesthesia, according to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intracranial pressure: Some consider the use of ketamine in patients with CNS masses, CNS abnormalities, or hydrocephalus a relative contraindication due to multiple reports that ketamine may increase intracranial pressure in these patients; use caution, especially at higher doses (ACEP [Green 2011]; Cohen 2018). However, assuming adequate ventilation, some evidence suggests that ketamine has minimal effects on intracranial pressure and may even improve cerebral perfusion and reduce intracranial pressure (Albanese 1997; Bowles 2012; Quibell 2015; Zeiler 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased ocular pressure: Use with caution in patients with increased intraocular pressure (IOP). Some recommend avoiding use in patients with an open eye injury or other ophthalmologic disorder where an increase in IOP would prove to be detrimental; however, the effects of ketamine on IOP is mixed with some evidence demonstrating no clinically significant effect on IOP (ACEP [Green 2011]; Cunningham 1986; Drayna 2012; Miller 2010; Nagdeve 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Liver injury: Recurrent use (eg, abuse/misuse, medically supervised unapproved use) may cause hepatobiliary dysfunction (usually a cholestatic pattern) and biliary duct dilatation with or without evidence of biliary obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: The ACEP considers the use of ketamine in patients with porphyria a relative contraindication due to enhanced sympathomimetic effect produced by ketamine (ACEP [Green 2011]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disorders: The ACEP considers the use of ketamine in patients with a thyroid disorder or receiving a thyroid medication a relative contraindication due to enhanced sympathomimetic effect produced by ketamine (ACEP [Green 2011]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrospinal fluid pressure elevation: Use with caution in patients with cerebrospinal fluid (CSF) pressure elevation; an increase in CSF pressure may be associated with use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Use with caution in patients with chronic alcohol use disorder or who are acutely alcohol-intoxicated..</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and attention deficit hyperactivity disorder. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel: Use requires careful patient monitoring, should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with deep anesthesia. Consult local regulations and individual institutional policies and procedures.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878508"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Postanesthetic emergence reactions may be minimized by limiting verbal, tactile, and visual patient stimulation during recovery, or by pretreatment with a benzodiazepine (using lower recommended doses of ketamine). Severe emergent reactions may require treatment with a small hypnotic dose of a short or ultrashort acting barbiturate.</p></div>
<div class="block foc drugH1Div" id="F185708"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ketalar: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL, 10 mL)</p></div>
<div class="block geq drugH1Div" id="F185693"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422244"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ketalar Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $1.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $0.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $3.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ketamine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $1.21 - $1.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $0.43 - $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $1.99 - $3.62</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867293"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ketalar: 10 mg/mL (20 mL); 50 mg/mL (10 mL) [contains benzethonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL, 20 mL); 50 mg/mL (2 mL, 10 mL)</p></div>
<div class="block csi drugH1Div" id="F185765"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-III</p></div>
<div class="block adm drugH1Div" id="F185710"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal</b> (off label): Administer half dose in each nostril using a needleless syringe or mucosal atomizer device. <b>Note:</b> Intranasal use for adults for procedural sedation is not recommended since volume limits an adequate dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28366351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28366351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral</b> (off label): May administer undiluted or mix the appropriate dose (using the injectable solution) in a flavoring agent (eg, simple syrup), cola, or other beverage; administer immediately after preparation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1729932','lexi-content-ref-26096492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1729932','lexi-content-ref-26096492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject deep IM into large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> According to the manufacturer, administer bolus/induction doses over 1 minute or at a rate of 0.5 mg/kg/minute; more rapid administration may result in respiratory depression and enhanced pressor response. Some experts suggest administration over 2 to 3 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.2010'])">Ref</a></span>). When used for treatment refractory unipolar depression, administer over 40 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28249076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28249076'])">Ref</a></span>). May also be administered as a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal</b> (off label): May use the 50 mg/mL solution undiluted or use the 100 mg/mL solution and further dilute prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11046209','lexi-content-ref-1890517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11046209','lexi-content-ref-1890517'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SubQ</b> (off label): May administer as a subcutaneous continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29870458','lexi-content-ref-14633551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29870458','lexi-content-ref-14633551'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613108"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Intranasal (using parenteral dosage form): Use the 50 or 100 mg/mL solution; may administer undiluted or further diluted in NS to a concentration of 20 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22046702','lexi-content-ref-8023666','lexi-content-ref-25095322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22046702','lexi-content-ref-8023666','lexi-content-ref-25095322'])">Ref</a></span>). Administer dose in 1 nostril (for volumes ≤0.5 mL) or divide dose and administer half dose in each nostril using a mucosal atomizer device (preferred) or needleless syringe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30592476','lexi-content-ref-25447557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30592476','lexi-content-ref-25447557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral (using parenteral dosage form): Use the 100 mg/mL IV solution and mix the appropriate dose in 0.2 to 0.4 mL/kg of cola, sour cherry juice, or other beverage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1729932','lexi-content-ref-1408506','lexi-content-ref-12553389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1729932','lexi-content-ref-1408506','lexi-content-ref-12553389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: May administer the 10 mg/mL and 50 mg/mL undiluted. Administer slowly over 60 seconds, do not exceed 0.5 mg/kg/minute; more rapid administration may result in respiratory depression and enhanced pressor response. Some experts suggest administration over 2 to 3 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.2010'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: May be administered as a continuous IV infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal (using parenteral dosage form): May use the 50 mg/mL solution undiluted or use the 100 mg/mL solution and further dilute prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11046209','lexi-content-ref-1890517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11046209','lexi-content-ref-1890517'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F185709"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Anesthesia:</b> Induction and maintenance of general anesthesia.</p></div>
<div class="block off-label drugH1Div" id="F25726701"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation, acute/severe or refractory; Analgesia, subanesthetic dosing, acute and chronic pain; Depressive episode (severe, treatment resistant) associated with major depressive disorder (unipolar); Mechanically ventilated patients in the ICU, analgesia/sedation/agitation; Procedural sedation; Rapid sequence intubation outside the operating room, induction; Status epilepticus, refractory</p></div>
<div class="block mst drugH1Div" id="F185772"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ketalar may be confused with Kenalog, ketorolac</p>
<p style="text-indent:2em;">Ketamine may be confused with ketorolac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV, intranasal/inhaled administration, parenteral used orally for sedation in children) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F185759"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (major), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F185702"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2B6 Inducers (Moderate): May decrease the serum concentration of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). Management: Avoid concomitant use of fexinidazole and CYP2B6 substrates when possible. If combined, monitor for reduced efficacy of the CYP2B6 substrate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the hypertensive effect of Ketamine. Levothyroxine may enhance the tachycardic effect of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Ketamine may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Ketamine may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, the risk for seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: Ketamine may enhance the adverse/toxic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticlopidine: May increase the serum concentration of Ketamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F5994626"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ketamine crosses the placenta (Ellingson 1977; Little 1972).</p>
<p style="text-indent:0em;margin-top:2em;">Ketamine produces dose dependent increases in uterine contractions; effects may vary by trimester. The plasma clearance of ketamine is reduced during pregnancy. Dose related neonatal depression and decreased Apgar scores have been reported with large doses administered at delivery (Little 1972; Neuman 2013; White 1982).</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Evaluate benefits and potential risks of fetal exposure to ketamine when duration of surgery is expected to be &gt;3 hours (Olutoye 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Although obstetric use is not recommended by the manufacturer, ketamine has been evaluated for use during cesarean and vaginal delivery (ACOG 209 2019; Akamatsu 1974; Galbert 1973). Ketamine may be considered as an alternative induction agent in females requiring general anesthesia for cesarean delivery who are hemodynamically unstable (Devroe 2015). Use of ketamine as an adjunctive analgesic in cesarean section has also been evaluated; however, use for this purpose may require additional studies (Carvalho 2017; Heesen 2015). When sedation and analgesia is needed for other procedures during pregnancy, low doses of ketamine may be used, but other agents are preferred (Neuman 2013; Schwenk 2018). Use of ketamine infusion for the treatment of refractory status epilepticus in a pregnant patient has been noted in a case report (Talahma 2018).</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that pregnant women should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).</p></div>
<div class="block brc drugH1Div" id="F16570985"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ketamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The Academy of Breast Feeding Medicine recommends postponing elective surgery until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;">Small supplemental doses of ketamine used during cesarean delivery should not prevent breastfeeding once the mother is stable and alert. However, data is insufficient to recommend use for long-term pain control (ABM [Martin 2018]).</p></div>
<div class="block mop drugH1Div" id="F185705"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Heart rate, blood pressure, respiratory rate, transcutaneous O<sub>2</sub> saturation, level of sedation, emergence reactions; cardiac function (continuously monitored in patients with increased blood pressure or cardiac decompensation); LFTs, alkaline phosphatase, and gamma glutamyl transferase (baseline and then at periodic intervals). When used for the treatment of pain, monitor pain control during therapy.</p></div>
<div class="block pha drugH1Div" id="F185696"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces a cataleptic-like state in which the patient is dissociated from the surrounding environment by direct action on the cortex and limbic system. Ketamine is a noncompetitive NMDA receptor antagonist that blocks glutamate. Low (subanesthetic) doses produce analgesia, and modulate central sensitization, hyperalgesia and opioid tolerance. Reduces polysynaptic spinal reflexes. </p></div>
<div class="block phk drugH1Div" id="F185712"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Anesthetic effect: Within 30 seconds</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Anesthetic effect: 3 to 4 minutes; Analgesia: Within 10 to 15 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Analgesic effect: Within 10 minutes (Carr 2004); Sedation: Children 2 to 6 years: 5 to 8 minutes (Bahetwar 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Analgesia: Within 30 minutes; Sedation: Children 2 to 8 years (Turhanoglu 2003):</p>
<p style="text-indent:-2em;margin-left:6em;">4 mg/kg/dose: 12.9 ± 1.9 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">6 mg/kg/dose: 10.4 ± 2.9 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">8 mg/kg/dose: 9.5 ± 1.9 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Anesthetic effect: 5 to 10 minutes; Recovery: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Anesthetic effect: 12 to 25 minutes; Analgesia: 15 to 30 minutes; Recovery: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Analgesic effect: Up to 60 minutes (Carr 2004); Recovery: Children 2 to 6 years: 34 to 46 minutes (Bahetwar 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 2.1 to 3.1 L/kg (Clements 1981)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 27% (Brunton 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via N-dealkylation (metabolite I [norketamine]), hydroxylation of the cyclohexone ring (metabolites III and IV), conjugation with glucuronic acid and dehydration of the hydroxylated metabolites to form the cyclohexene derivative (metabolite II); metabolite I (norketamine) is 33% as potent as parent compound. When administered orally, norketamine concentrations are higher compared to other routes of administration due to extensive first-pass metabolism in the liver (Blonk 2010; Soto 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: 93%</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 20% to 30% (Miller 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Children, Adolescents, and Adults: Mean range: 35% to 50% (Malinovsky 1996; Miller 2010; Nielsen 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Children 2 to 9 years: 25% (Malinovsky 1996)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Alpha: 10 to 15 minutes; Beta: 2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: 5 to 30 minutes (Clements 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: 10 to 14 minutes (Huge 2010); Children 2 to 9 years: ~20 minutes (Malinovsky 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: ~30 minutes (Soto 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Children 2 to 9 years: ~45 minutes (Malinovsky 1996)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (91%); feces (3%) (Ghoneim 1977)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F185716"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Inducmina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ketamine interpharma</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Kain</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ketamin sintetica</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Calypsol | Ketalar | Narkamon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ketamin curamed</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ketanest</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ketalar | Narkamon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ketalar | Narkamon</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ketamine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Calypsol | Ketlar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ketalar | Ketamin Inresa | Narkamon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ketamine HCL</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tekam</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ketalar | Ketamin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ketanest</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Calypsol | Narkamon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ketalar | Ketomin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ketalar</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Keiran</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Micro ketamine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19897179">
<a name="19897179"></a>aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. <i>Biol Psychiatry</i>. 2010;67(2):139-145. doi:10.1016/j.biopsych.2009.08.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19897179/pubmed" id="19897179" target="_blank">19897179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33120301">
<a name="33120301"></a>Adhikary SD, Thiruvenkatarajan V, McFadden A, Liu WM, Mets B, Rogers A. Analgesic efficacy of ketamine and magnesium after laparoscopic sleeve gastrectomy: a randomized, double-blind, placebo-controlled trial. <i>J Clin Anesth</i>. 2021;68:110097. doi:10.1016/j.jclinane.2020.110097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33120301/pubmed" id="33120301" target="_blank">33120301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4856139">
<a name="4856139"></a>Akamatsu TJ, Bonica JJ, Rehmet R, Eng M, Ueland K. Experiences with the use of ketamine for parturition. I. Primary anesthetic for vaginal delivery. <i>Anesth Analg</i>. 1974;53(2):284-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/4856139/pubmed" id="4856139" target="_blank">4856139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30611640">
<a name="30611640"></a>Akhlaghi N, Payandemehr P, Yaseri M, Akhlaghi AA, Abdolrazaghnejad A. Premedication with midazolam or haloperidol to prevent recovery agitation in adults undergoing procedural sedation with ketamine: a randomized double-blind clinical trial. <i>Ann Emerg Med</i>. 2019;73(5):462-469. doi:10.1016/j.annemergmed.2018.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30611640/pubmed" id="30611640" target="_blank">30611640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9416717">
<a name="9416717"></a>Albanèse J, Arnaud S, Rey M, Thomachot L, Alliez B, Martin C. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. <i>Anesthesiology</i>. 1997;87(6):1328-1334. doi:10.1097/00000542-199712000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9416717/pubmed" id="9416717" target="_blank">9416717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23222112">
<a name="23222112"></a>Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use for pediatric sedation. <i>Pediatr Emerg Care</i>. 2012;28(12):1391-1395; quiz 1396-8. doi:10.1097/PEC.0b013e318276fde2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23222112/pubmed" id="23222112" target="_blank">23222112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019;133(4):e285-e286. doi:10.1097/AOG.0000000000003174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11177093">
<a name="11177093"></a>Anand KJ, International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. <i>Arch Pediatr Adolesc Med</i>. 2001;155(2):173-180. doi:10.1001/archpedi.155.2.173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/11177093/pubmed" id="11177093" target="_blank">11177093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22401952">
<a name="22401952"></a>Andolfatto G, Abu-Laban RB, Zed PJ, et al. Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial.<i> Ann Emerg Med</i>. 2012;59(6):504-512.e1-e2. doi:10.1016/j.annemergmed.2012.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22401952/pubmed" id="22401952" target="_blank">22401952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24127709">
<a name="24127709"></a>Andolfatto G, Willman E, Joo D, et al. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. <i>Acad Emerg Med</i>. 2013;20(10):1050-1054. doi:10.1111/acem.12229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24127709/pubmed" id="24127709" target="_blank">24127709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19546251">
<a name="19546251"></a>Aroni F, Iacovidou N, Dontas I, Pourzitaki C, Xanthos T. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. <i>J Clin Pharmacol</i>. 2009;49(8):957-964. doi:10.1177/0091270009337941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19546251/pubmed" id="19546251" target="_blank">19546251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23364373">
<a name="23364373"></a>Asadi P, Ghafouri HB, Yasinzadeh M, Kasnavieh SM, Modirian E. Ketamine and atropine for pediatric sedation: a prospective double-blind randomized controlled trial. <i>Pediatr Emerg Care</i>. 2013;29(2):136-139. doi:10.1097/PEC.0b013e31828058b2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23364373/pubmed" id="23364373" target="_blank">23364373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22046702">
<a name="22046702"></a>Bahetwar SK, Pandey RK, Saksena AK, Chandra G. A comparative evaluation of intranasal midazolam, ketamine and their combination for sedation of young uncooperative pediatric dental patients: a triple blind randomized crossover trial. <i>J Clin Pediatr Dent.</i> 2011;35(4):415-420. doi:10.17796/jcpd.35.4.l43h3354705u2574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22046702/pubmed" id="22046702" target="_blank">22046702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23188232">
<a name="23188232"></a>Ballow SL, Kaups KL, Anderson S, Chang M. A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients. <i>J Trauma Acute Care Surg</i>. 2012;73(6):1401-1405. doi:10.1097/TA.0b013e318270dcf5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23188232/pubmed" id="23188232" target="_blank">23188232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23686730">
<a name="23686730"></a>Barkan S, Breitbart R, Brenner-Zada G, et al. A double-blind, randomised, placebo-controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair. <i>Emerg Med J</i>. 2014;31(8):649-653. doi:10.1136/emermed-2012-202189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23686730/pubmed" id="23686730" target="_blank">23686730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24963149">
<a name="24963149"></a>Barnard EB, Moy RJ, Kehoe AD, Bebarta VS, Smith JE. Rapid sequence induction of anaesthesia via the intraosseous route: a prospective observational study. <i>Emerg Med J</i>. 2015;32(6):449-452. doi:10.1136/emermed-2014-203740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24963149/pubmed" id="24963149" target="_blank">24963149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24015945">
<a name="24015945"></a>Barois J, Tourneux P. Ketamine and atropine decrease pain for preterm newborn tracheal intubation in the delivery room: an observational pilot study. <i>Acta Paediatr</i>. 2013;102(12):e534-538. doi:10.1111/apa.12413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24015945/pubmed" id="24015945" target="_blank">24015945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med.</i> 2013;41(1):263-306. doi:10.1097/CCM.0b013e3182783b72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33115424">
<a name="33115424"></a>Beaudequin D, Can AT, Dutton M, et al. Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support. <i>BMC Psychiatry</i>. 2020;20(1):519. doi:10.1186/s12888-020-02925-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33115424/pubmed" id="33115424" target="_blank">33115424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1443705">
<a name="1443705"></a>Beebe DS, Belani KG, Chang PN, et al. Effectiveness of preoperative sedation with rectal midazolam, ketamine, or their combination in young children. <i>Anesth Analg</i>. 1992;75(6):880-884. doi:10.1213/00000539-199212000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1443705/pubmed" id="1443705" target="_blank">1443705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15006978">
<a name="15006978"></a>Berkenbosch JW, Graff GR, Stark JM. Safety and efficacy of ketamine sedation for infant flexible fiberoptic bronchoscopy. <i>Chest</i>. 2004;125(3):1132-1137. doi:10.1378/chest.125.3.1132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15006978/pubmed" id="15006978" target="_blank">15006978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19879174">
<a name="19879174"></a>Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: a review. <i>Eur J Pain</i>. 2010;14(5):466-472. doi:10.1016/j.ejpain.2009.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19879174/pubmed" id="19879174" target="_blank">19879174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16703233">
<a name="16703233"></a>Bovill JG. Intravenous anesthesia for the patient with left ventricular dysfunction. <i>Semin Cardiothorac Vasc Anesth</i>. 2006;10(1):43-48. doi: 10.1177/108925320601000108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/16703233/pubmed" id="16703233" target="_blank">16703233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23409639">
<a name="23409639"></a>Bowles ED, Gold ME. Rethinking the paradigm: evaluation of ketamine as a neurosurgical anesthetic [published correction appears in <i>AANA J</i>. 2013;81(1):18.]. <i>AANA J</i>. 2012;80(6):445-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23409639/pubmed" id="23409639" target="_blank">23409639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bravenec.1">
<a name="Bravenec.1"></a>Bravenec B. General anesthesia: Intravenous induction agents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23. doi:10.1007/s12028-012-9695-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brunton.2006">
<a name="Brunton.2006"></a>Brunton LL, Lazo JS, Park KL, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 11th ed. McGraw-Hill Medical; 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28468568">
<a name="28468568"></a>Buchheit JL, Yeh DD, Eikermann M, Lin H. Impact of low-dose ketamine on the usage of continuous opioid infusion for the treatment of pain in adult mechanically ventilated patients in surgical intensive care units. <i>J Intensive Care Med</i>. 2019;34(8):646-651. doi:10.1177/0885066617706907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28468568/pubmed" id="28468568" target="_blank">28468568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2417535">
<a name="2417535"></a>Cabbabe EB, Behbahani PM. Cardiovascular reactions associated with the use of ketamine and epinephrine in plastic surgery. <i>Ann Plast Surg</i>. 1985;15(1):50-56. doi:10.1097/00000637-198507000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2417535/pubmed" id="2417535" target="_blank">2417535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15109503">
<a name="15109503"></a>Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. <i>Pain</i>. 2004;108(1-2):17-27. doi:10.1016/j.pain.2003.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15109503/pubmed" id="15109503" target="_blank">15109503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28625307">
<a name="28625307"></a>Carvalho B, Butwick AJ. Postcesarean delivery analgesia. <i>Best Pract Res Clin Anaesthesiol.</i> 2017;31(1):69-79. doi:10.1016/j.bpa.2017.01.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28625307/pubmed" id="28625307" target="_blank">28625307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14962334">
<a name="14962334"></a>Castilla M, Jerez M, Llácer M, Martinez S. Anaesthetic management in a neonate with congenital complete heart block. <i>Paediatr Anaesth</i>. 2004;14(2):172-175. doi:10.1046/j.1460-9592.2003.01180.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/14962334/pubmed" id="14962334" target="_blank">14962334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22248834">
<a name="22248834"></a>Chen CH, Lee MH, Chen YC, Lin MF. Ketamine-snorting associated cystitis. <i>J Formos Med Assoc</i>. 2011;110(12):787-791. doi:10.1016/j.jfma.2011.11.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22248834/pubmed" id="22248834" target="_blank">22248834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17038218">
<a name="17038218"></a>Cherng CH, Wong CS. Ketamine-induced emergence reactions after desflurane anaesthesia. <i>Eur J Anaesthesiol</i>. 2007;24(2):200-201. doi:10.1017/S0265021506001773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17038218/pubmed" id="17038218" target="_blank">17038218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33404393">
<a name="33404393"></a>Chow TG, McConnell J, Lee MJ. A 2-year-old girl with periprocedural anaphylaxis. <i>Allergy Asthma Proc</i>. 2021;42(1):97-99. doi:10.2500/aap.2021.42.200031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33404393/pubmed" id="33404393" target="_blank">33404393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10730829">
<a name="10730829"></a>Chudnofsky CR, Weber JE, Stoyanoff PJ, et al. A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients. <i>Acad Emerg Med</i>. 2000;7(3):228-235. doi:10.1111/j.1553-2712.2000.tb01064.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10730829/pubmed" id="10730829" target="_blank">10730829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7097501">
<a name="7097501"></a>Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. <i>J Pharm Sci</i>. 1982;71(5):539-542. doi:10.1002/jps.2600710516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7097501/pubmed" id="7097501" target="_blank">7097501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7459184">
<a name="7459184"></a>Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. <i>Br J Anaesth</i>. 1981;53(1):27-30. doi:10.1093/bja/53.1.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7459184/pubmed" id="7459184" target="_blank">7459184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25064742">
<a name="25064742"></a>Cohen L, Athaide V, Wickham ME, Doyle-Waters MM, Rose NG, Hohl CM. The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review. <i>Ann Emerg Med</i>. 2015;65(1):43-51.e2. doi:10.1016/j.annemergmed.2014.06.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25064742/pubmed" id="25064742" target="_blank">25064742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29870458">
<a name="29870458"></a>Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. <i>Reg Anesth Pain Med</i>. 2018;43(5):521-546. doi:10.1097/AAP.0000000000000808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29870458/pubmed" id="29870458" target="_blank">29870458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29033344">
<a name="29033344"></a>Cole JB, Klein LR, Nystrom PC, et al. A prospective study of ketamine as primary therapy for prehospital profound agitation. <i>Am J Emerg Med.</i> 2018;36(5):789-796. doi:10.1016/j.ajem.2017.10.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29033344/pubmed" id="29033344" target="_blank">29033344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102743">
<a name="27102743"></a>Cole JB, Moore JC, Nystrom PC, et al. A prospective study of ketamine versus haloperidol for severe prehospital agitation. <i>Clin Toxicol (Phila)</i>. 2016;54(7):556-562. doi:10.1080/15563650.2016.1177652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27102743/pubmed" id="27102743" target="_blank">27102743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26346210">
<a name="26346210"></a>Corrigan M, Wilson SS, Hampton J. Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. <i>Am J Health Syst Pharm</i>. 2015;72(18):1544-1554. doi:10.2146/ajhp140630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26346210/pubmed" id="26346210" target="_blank">26346210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259826">
<a name="32259826"></a>Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. <i>Psychother Psychosom</i>. 2020;89(5):283-306. doi:10.1159/000506868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/32259826/pubmed" id="32259826" target="_blank">32259826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8295806">
<a name="8295806"></a>Cote CJ. Sedation for the Pediatric Patient: A Review. <i>Pediatr Clin North Am.</i> 1994;41(1):31-58. doi:10.1016/s0031-3955(16)38690-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8295806/pubmed" id="8295806" target="_blank">8295806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.2013">
<a name="Cote.2013"></a>Coté CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia for Infants and Children.</i> 5th ed. Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.2019">
<a name="Cote.2019"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34699023">
<a name="34699023"></a>Cotter S, Wong J, Gada N, et al. Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: a retrospective case series. <i>Drug Saf</i>. 2021;44(12):1365-1374. doi:10.1007/s40264-021-01120-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/34699023/pubmed" id="34699023" target="_blank">34699023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16869851">
<a name="16869851"></a>Critchlow DG. A case of ketamine dependence with discontinuation symptoms. <i>Addiction</i>. 2006;101(8):1212-1213. doi:10.1111/j.1360-0443.2006.01494.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/16869851/pubmed" id="16869851" target="_blank">16869851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3516335">
<a name="3516335"></a>Cunningham AJ, Barry P. Intraocular pressure--physiology and implications for anaesthetic management. <i>Can Anaesth Soc J</i>. 1986;33(2):195-208. doi:10.1007/BF03010831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/3516335/pubmed" id="3516335" target="_blank">3516335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21256626">
<a name="21256626"></a>David H, Shipp J. A randomized controlled trial of ketamine/propofol versus propofol alone for emergency department procedural sedation. <i>Ann Emerg Med</i>. 2011;57(5):435-441. doi:10.1016/j.annemergmed.2010.11.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21256626/pubmed" id="21256626" target="_blank">21256626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28979485">
<a name="28979485"></a>Davis J, Bates L. Rapid sequence induction via an intraosseous needle. <i>J Intensive Care Soc</i>. 2016;17(2):178-179. doi:10.1177/1751143715614845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28979485/pubmed" id="28979485" target="_blank">28979485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16567251">
<a name="16567251"></a>Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. <i>J Emerg Med</i>. 2006;30(2):163-166. doi:10.1016/j.jemermed.2005.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/16567251/pubmed" id="16567251" target="_blank">16567251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al; Society of Critical Care Medicine. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25827280">
<a name="25827280"></a>Devroe S, Van de Velde M, Rex S. General anesthesia for caesarean section. <i>Curr Opin Anaesthesiol</i>. 2015;28(3):240-246. doi:10.1097/ACO.0000000000000185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25827280/pubmed" id="25827280" target="_blank">25827280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9243683">
<a name="9243683"></a>Diaz JH. Intranasal ketamine preinduction of paediatric outpatients. <i>Paediatr Anaesth</i>. 1997;7(4):273-278. doi:10.1046/j.1460-9592.1997.d01-93.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9243683/pubmed" id="9243683" target="_blank">9243683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22169582">
<a name="22169582"></a>Drayna PC, Estrada C, Wang W, Saville BR, Arnold DH. Ketamine sedation is not associated with clinically meaningful elevation of intraocular pressure. <i>Am J Emerg Med</i>. 2012;30(7):1215-1218. doi:10.1016/j.ajem.2011.06.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22169582/pubmed" id="22169582" target="_blank">22169582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27692755">
<a name="27692755"></a>Driver BE, Reardon RF. Apnea after low-dose ketamine sedation during attempted delayed sequence intubation. <i>Ann Emerg Med</i>. 2017;69(1):34-35. doi:10.1016/j.annemergmed.2016.07.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27692755/pubmed" id="27692755" target="_blank">27692755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-842268">
<a name="842268"></a>Ellingson A, Haram K, Sagen N, Solheim E. Transplacental passage of ketamine after intravenous administration. <i>Acta Anaesthesiol Scand</i>. 1977;21(1):41-44. doi:10.1111/j.1399-6576.1977.tb01191.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/842268/pubmed" id="842268" target="_blank">842268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32513237">
<a name="32513237"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. <i>Crit Care</i>. 2020;24(1):315. doi:10.1186/s13054-020-03040-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/32513237/pubmed" id="32513237" target="_blank">32513237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29364490">
<a name="29364490"></a>Fantacci C, Fabrizio GC, Ferrara P, Franceschi F, Chiaretti A. Intranasal drug administration for procedural sedation in children admitted to pediatric emergency room. <i>Eur Rev Med Pharmacol Sci</i>. 2018;22(1):217-222. doi:10.26355/eurrev_201801_14120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29364490/pubmed" id="29364490" target="_blank">29364490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30283029">
<a name="30283029"></a>Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Mol Psychiatry.</i> 2020;25(7):1592-1603. doi:10.1038/s41380-018-0256-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30283029/pubmed" id="30283029" target="_blank">30283029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Drug Safety Communication. FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. Food and Drug Administration website. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Accessed May 26, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32665505">
<a name="32665505"></a>Ferguson CL, Beckett RD. Intranasal ketamine for treatment of acute pain in pediatrics: a systematic review. <i>Pediatr Emerg Care</i>. 2020;36(8):e476-e481. doi:10.1097/PEC.0000000000002181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/32665505/pubmed" id="32665505" target="_blank">32665505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27460905">
<a name="27460905"></a>Ferguson I, Bell A, Treston G, New L, Ding M, Holdgate A. Propofol or ketofol for procedural sedation and analgesia in emergency medicine-the POKER study: a randomized double-blind clinical trial. <i>Ann Emerg Med</i>. 2016;68(5):574-582.e1. doi:10.1016/j.annemergmed.2016.05.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27460905/pubmed" id="27460905" target="_blank">27460905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30921252">
<a name="30921252"></a>Fishman DS, Andropoulos DB, Lightdale JR. Sedation and the Food and Drug Administration warning: what a pediatric gastroenterologist, hepatologist, and pancreatologist should know. <i>J Pediatr Gastroenterol Nutr</i>. 2019;69(1):3-5. doi:10.1097/MPG.0000000000002346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30921252/pubmed" id="30921252" target="_blank">30921252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25038867">
<a name="25038867"></a>Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. <i>Psychopharmacology (Berl)</i>. 2014;231(18):3663-3676. doi:10.1007/s00213-014-3664-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25038867/pubmed" id="25038867" target="_blank">25038867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30592476">
<a name="30592476"></a>Frey TM, Florin TA, Caruso M, Zhang N, Zhang Y, Mittiga MR. Effect of intranasal ketamine vs fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial. <i>JAMA Pediatr</i>. 2019;173(2):140-146. doi:10.1001/jamapediatrics.2018.4582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30592476/pubmed" id="30592476" target="_blank">30592476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.2011">
<a name="Fuhrman.2011"></a>Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4796568">
<a name="4796568"></a>Galbert MW, Gardner AE. Ketamine for obstetrical anesthesia. <i>Anesth Analg.</i> 1973;52(6):926-930.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/4796568/pubmed" id="4796568" target="_blank">4796568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30746728">
<a name="30746728"></a>Garber PM, Droege CA, Carter KE, Harger NJ, Mueller EW. Continuous infusion ketamine for adjunctive analgosedation in mechanically ventilated, critically ill patients. <i>Pharmacotherapy</i>. 2019;39(3):288-296. doi:10.1002/phar.2223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30746728/pubmed" id="30746728" target="_blank">30746728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24813545">
<a name="24813545"></a>Garg A, Sinha P, Kumar P, Prakash O. Use of naltrexone in ketamine dependence. <i>Addict Behav</i>. 2014;39(8):1215-1216. doi:10.1016/j.addbeh.2014.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24813545/pubmed" id="24813545" target="_blank">24813545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23758557">
<a name="23758557"></a>Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. <i>Epilepsia</i>. 2013;54(8):1498-1503. doi:10.1111/epi.12247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23758557/pubmed" id="23758557" target="_blank">23758557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18092436">
<a name="18092436"></a>Gautam SN, Bhatta S, Sangraula D, Shrestha BC, Rawal SB. Intranasal midazolam vs ketamine as premedication in paediatric surgical procedure for child separation and induction. <i>Nepal Med Coll J</i>. 2007;9(3):179-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18092436/pubmed" id="18092436" target="_blank">18092436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Geiger-Hayes.1">
<a name="Geiger-Hayes.1"></a>Geiger-Hayes J. PAINWeek journal vol 6, Q4. https://www.painweek.org/media/journal/pwj-painweek-journal-vol-6-q4. Published 2018. Accessed July 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8602672">
<a name="8602672"></a>Gelissen HP, Epema AH, Henning RH, Krijnen HJ, Hennis PJ, den Hertog A. Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. <i>Anesthesiology</i>. 1996;84(2):397-403. doi:10.1097/00000542-199602000-00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8602672/pubmed" id="8602672" target="_blank">8602672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21053">
<a name="21053"></a>Ghoneim MM, Korttila K. Pharmacokinetics of Intravenous Anaesthetics: Implications for Clinical Use. <i>Clin Pharmacokinet.</i> 1977;2(5):344-372. doi:10.2165/00003088-197702050-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21053/pubmed" id="21053" target="_blank">21053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24438649">
<a name="24438649"></a>Godwin SA, Burton JH, Gerardo CJ, et al; American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2014;63(2):247-258.e18. doi:10.1016/j.annemergmed.2013.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24438649/pubmed" id="24438649" target="_blank">24438649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33489089">
<a name="33489089"></a>Gómez-Revuelta M, Fernández-Rodríguez M, Boada-Antón L, Vázquez-Bourgon J. Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression. <i>Ther Adv Psychopharmacol</i>. 2020;10:2045125320981498. doi:10.1177/2045125320981498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33489089/pubmed" id="33489089" target="_blank">33489089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25035566">
<a name="25035566"></a>Goyal S, Ambekar A, Ray R. Ketamine dependence in an anesthesiologist: an occupational hazard? <i>Indian J Psychol Med</i>. 2014;36(3):335-337. doi:10.4103/0253-7176.135395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25035566/pubmed" id="25035566" target="_blank">25035566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33509654">
<a name="33509654"></a>Grabowski J, Goldin A, Arthur LG, et al. The effects of early anesthesia on neurodevelopment: a systematic review. <i>J Pediatr Surg</i>. 2021:S0022-3468(21)00014-2. doi:10.1016/j.jpedsurg.2021.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33509654/pubmed" id="33509654" target="_blank">33509654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28915132">
<a name="28915132"></a>Graham MR. Clinical update regarding general anesthesia-associated neurotoxicity in infants and children. <i>Curr Opin Anaesthesiol</i>. 2017;30(6):682-687. doi:10.1097/ACO.0000000000000520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28915132/pubmed" id="28915132" target="_blank">28915132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25447557">
<a name="25447557"></a>Graudins A, Meek R, Egerton-Warburton D, Oakley E, Seith R. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. <i>Ann Emerg Med</i>. 2015;65(3):248-254.e1. doi:10.1016/j.annemergmed.2014.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25447557/pubmed" id="25447557" target="_blank">25447557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21256625">
<a name="21256625"></a>Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. <i>Ann Emerg Med.</i> 2011;57(5):449-461. doi:10.1016/j.annemergmed.2010.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21256625/pubmed" id="21256625" target="_blank">21256625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19201064">
<a name="19201064"></a>Green SM, Roback MG, Krauss B, et al; Emergency Department Ketamine Meta-Analysis Study Group. Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. <i>Ann Emerg Med</i>. 2009;54(2):158-68.e1-4. doi:10.1016/j.annemergmed.2008.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19201064/pubmed" id="19201064" target="_blank">19201064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15765332">
<a name="15765332"></a>Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. <i>Am J Emerg Med</i>. 2005;23(2):142-144. doi:10.1016/j.ajem.2004.04.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15765332/pubmed" id="15765332" target="_blank">15765332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29193185">
<a name="29193185"></a>Groetzinger LM, Rivosecchi RM, Bain W, et al. Ketamine infusion for adjunct sedation in mechanically ventilated adults. <i>Pharmacotherapy</i>. 2018;38(2):181-188. doi:10.1002/phar.2065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29193185/pubmed" id="29193185" target="_blank">29193185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.2019">
<a name="Gropper.2019"></a>Gropper MA, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Leslie K. <i>Miller’s Anesthesia.</i> 9th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21507125">
<a name="21507125"></a>Guerra GG, Robertson CM, Alton GY, et al; Western Canadian Complex Pediatric Therapies Follow-up Group. Neurodevelopmental outcome following exposure to sedative and analgesic drugs for complex cardiac surgery in infancy. <i>Paediatr Anaesth</i>. 2011;21(9):932-941. doi:10.1111/j.1460-9592.2011.03581.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21507125/pubmed" id="21507125" target="_blank">21507125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31290798">
<a name="31290798"></a>Guthrie AM, Baum RA, Carter C, et al. Use of intranasal ketamine in pediatric patients in the emergency department. <i>Pediatr Emerg Care</i>. Published online July 8, 2019. doi:10.1097/PEC.0000000000001863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31290798/pubmed" id="31290798" target="_blank">31290798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1729932">
<a name="1729932"></a>Gutstein HB, Johnson KL, Heard MB, Gregory GA. Oral ketamine preanesthetic medication in children. <i>Anesthesiology</i>. 1992;76(1):28-33. doi:10.1097/00000542-199201000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1729932/pubmed" id="1729932" target="_blank">1729932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1308374">
<a name="1308374"></a>Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. <i>Anesth Prog</i>. 1992;39(3):61-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1308374/pubmed" id="1308374" target="_blank">1308374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22341549">
<a name="22341549"></a>Hall RW. Anesthesia and analgesia in the NICU. <i>Clin Perinatol</i>. 2012;39(1):239-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22341549/pubmed" id="22341549" target="_blank">22341549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25225198">
<a name="25225198"></a>Hatab SZ, Singh A, Felner EI, Kamat P. Transient central diabetes insipidus induced by ketamine infusion.<i> Ann Pharmacother</i>. 2014;48(12):1642-1645. doi:10.1177/1060028014549991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25225198/pubmed" id="25225198" target="_blank">25225198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25789942">
<a name="25789942"></a>Heesen M, Böhmer J, Brinck EC, Kontinen VK, Klöhr S, Rossaint R, Straube S. Intravenous ketamine during spinal and general anaesthesia for caesarean section: systematic review and meta-analysis. <i>Acta Anaesthesiol Scand</i>. 2015;59(4):414-426. doi:10.1111/aas.12468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25789942/pubmed" id="25789942" target="_blank">25789942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.doi:10.1542/peds.2007-3284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343462">
<a name="15343462"></a>Heinrich M, Wetzstein V, Muensterer OJ, Till H. Conscious sedation: Off-label use of rectal S(+)-ketamine and midazolam for wound dressing changes in paediatric heat injuries. <i>Eur J Pediatr Surg</i>. 2004;14(4):235-239. doi:10.1055/s-2004-817960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15343462/pubmed" id="15343462" target="_blank">15343462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30402516">
<a name="30402516"></a>Heydari F, Gholamian A, Zamani M, Majidinejad S. Effect of intramuscular ketamine versus haloperidol on short-term control of severe agitated patients in emergency department; a randomized clinical trial. <i>Bull Emerg Trauma</i>. 2018;6(4):292-299. doi:10.29252/beat-060404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30402516/pubmed" id="30402516" target="_blank">30402516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14633551">
<a name="14633551"></a>Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. <i>Anesth Analg. </i>2003;97(6):1730-1739. doi:10.1213/01.ANE.0000086618.28845.9B<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/14633551/pubmed" id="14633551" target="_blank">14633551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19733106">
<a name="19733106"></a>Huge V, Lauchart M, Magerl W, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. <i>Eur J Pain</i>. 2010;14(4):387-394. doi:10.1016/j.ejpain.2009.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19733106/pubmed" id="19733106" target="_blank">19733106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9872743">
<a name="9872743"></a>Ikonomidou C, Bosch F, Miksa M, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. <i>Science</i>. 1999;283(5398):70-74. doi:10.1126/science.283.5398.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9872743/pubmed" id="9872743" target="_blank">9872743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32426747">
<a name="32426747"></a>Iqbal O'Meara AM, Miller Ferguson N, Zven SE, et al. Potential neurodevelopmental effects of pediatric intensive care sedation and analgesia: repetitive benzodiazepine and opioid exposure alters expression of glial and synaptic proteins in juvenile rats. <i>Crit Care Explor</i>. 2020;2(4):e0105. doi:10.1097/CCE.0000000000000105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/32426747/pubmed" id="32426747" target="_blank">32426747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899459">
<a name="26899459"></a>Isbister GK, Calver LA, Downes MA, Page CB. Ketamine as rescue treatment for difficult-to-sedate severe acute behavioral disturbance in the emergency department. <i>Ann Emerg Med</i>. 2016;67(5):581-587.e1. doi:10.1016/j.annemergmed.2015.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26899459/pubmed" id="26899459" target="_blank">26899459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19573904">
<a name="19573904"></a>Jabre P, Combes X, Lapostolle F, et al; KETASED Collaborative Study Group. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. <i>Lancet</i>. 2009;374(9686):293-300. doi:10.1016/S0140-6736(09)60949-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19573904/pubmed" id="19573904" target="_blank">19573904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12545318">
<a name="12545318"></a>Jobeir A, Galal MO, Bulbul ZR, Solymar L, Darwish A, Schmaltz AA. Use of low-dose ketamine and/or midazolam for pediatric cardiac catheterization. <i>Pediatr Cardiol</i>. 2003;24(3):236-243. doi:10.1007/s00246-002-0339-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12545318/pubmed" id="12545318" target="_blank">12545318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24149025">
<a name="24149025"></a>Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. <i>Emerg Health Threats J</i>. 2011;4:7107. doi:10.3402/ehtj.v4i0.7107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24149025/pubmed" id="24149025" target="_blank">24149025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11779670">
<a name="11779670"></a>Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.<i> J Pain Symptom Manage.</i> 2002;23(1):60-65. doi:10.1016/s0885-3924(01)00373-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/11779670/pubmed" id="11779670" target="_blank">11779670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ketalar.2020.08">
<a name="Ketalar.2020.08"></a>Ketalar (ketamine hydrochloride) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ketalar.2020.10">
<a name="Ketalar.2020.10"></a>Ketalar (ketamine hydrochloride) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ketamine.2013.01">
<a name="Ketamine.2013.01"></a>Ketamine hydrochloride injection [prescribing information]. Lake Forest, IL: Hospira Inc; January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khorsand.1">
<a name="Khorsand.1"></a>Khorsand SM. Maintenance of general anesthesia: overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2020. .</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33000033">
<a name="33000033"></a>Kitch BB. Out-of-hospital ketamine: review of a growing trend in patient care. <i>J Am Coll Emerg Physicians Open</i>. 2020;1(3):183-189. doi:10.1002/emp2.12023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33000033/pubmed" id="33000033" target="_blank">33000033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20924617">
<a name="20924617"></a>Koruk S, Mizrak A, Gul R, Kilic E, Yendi F, Oner U. Dexmedetomidine-ketamine and midazolam-ketamine combinations for sedation in pediatric patients undergoing extracorporeal shock wave lithotripsy: a randomized prospective study. <i>J Anesth</i>. 2010;24(6):858-863. doi:10.1007/s00540-010-1023-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20924617/pubmed" id="20924617" target="_blank">20924617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22237581">
<a name="22237581"></a>Kramer AH. Early ketamine to treat refractory status epilepticus. <i>Neurocrit Care</i>. 2012;16(2):299-305. doi:10.1007/s12028-011-9668-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22237581/pubmed" id="22237581" target="_blank">22237581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32301056">
<a name="32301056"></a>Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. <i>Pharmacol Rep</i>. 2020;72(3):543-562. doi:10.1007/s43440-020-00097-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/32301056/pubmed" id="32301056" target="_blank">32301056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19484828">
<a name="19484828"></a>Lago P, Garetti E, Merazzi D, et al. Guidelines for procedural pain in the newborn. <i>Acta Paediatr</i>. 2009;98(6):932-939. doi:10.1111/j.1651-2227.2009.01291.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19484828/pubmed" id="19484828" target="_blank">19484828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8526975">
<a name="8526975"></a>Lahti AC, Koffel B, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. <i>Neuropsychopharmacology</i>. 1995;13(1):9-19. doi:10.1016/0893-133X(94)00131-I<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8526975/pubmed" id="8526975" target="_blank">8526975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22710265">
<a name="22710265"></a>Lai Y, Wu S, Ni L, Chen Z, Li X, Yang S, Gui Y, Guan Z, Cai Z, Ye J. Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity. <i>Urol Int</i>. 2012;89(1):93-96. doi:10.1159/000338098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22710265/pubmed" id="22710265" target="_blank">22710265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27544138">
<a name="27544138"></a>Legriel S, Oddo M, Brophy GM. What's new in refractory status epilepticus? <i>Intensive Care Med</i>. 2017;43(4):543-546. doi:10.1007/s00134-016-4501-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27544138/pubmed" id="27544138" target="_blank">27544138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31735659">
<a name="31735659"></a>Li M, Martinelli AN, Oliver WD, Wilkerson RG. Evaluation of ketamine for excited delirium syndrome in the adult emergency department. <i>J Emerg Med.</i> 2019;S0736-S4679(19)30802-9. doi:10.1016/j.jemermed.2019.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31735659/pubmed" id="31735659" target="_blank">31735659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12762561">
<a name="12762561"></a>Lim DK. Ketamine associated psychedelic effects and dependence. <i>Singapore Med J</i>. 2003;44(1):31-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12762561/pubmed" id="12762561" target="_blank">12762561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675923">
<a name="15675923"></a>Lin C, Durieux ME. Ketamine and kids: an update. <i>Paediatr Anaesth</i>. 2005;15(2):91-97. doi:10.1111/j.1460-9592.2005.01475.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15675923/pubmed" id="15675923" target="_blank">15675923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26757313">
<a name="26757313"></a>Lin PC, Lane HY, Lin CH. Spontaneous remission of ketamine withdrawal-related depression. <i>Clin Neuropharmacol</i>. 2016;39(1):51-52. doi:10.1097/WNF.0000000000000121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26757313/pubmed" id="26757313" target="_blank">26757313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2215104">
<a name="2215104"></a>Lin SM, Liu K, Tsai SK, Lee TY. Rectal ketamine versus intranasal ketamine as premedicant in children. <i>Ma Zui Xue Za Zhi</i>. 1990;28(2):177-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2215104/pubmed" id="2215104" target="_blank">2215104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29136301">
<a name="29136301"></a>Linder LM, Ross CA, Weant KA. Ketamine for the acute management of excited delirium and agitation in the prehospital setting. <i>Pharmacotherapy</i>. 2018;38(1):139-151. doi:10.1002/phar.2060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29136301/pubmed" id="29136301" target="_blank">29136301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5006995">
<a name="5006995"></a>List WF, Crumrine RS, Cascorbi HF, Weiss MH. Increased cerebrospinal fluid pressure after ketamine. <i>Anesthesiology</i>. 1972;36(1):98-99. doi:10.1097/00000542-197201000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/5006995/pubmed" id="5006995" target="_blank">5006995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4554554">
<a name="4554554"></a>Little B, Chang T, Chucot L, et al. Study of ketamine as an obstetric anesthetic agent. <i>Am J Obstet Gynecol. </i>1972;15:113(2):247-260. doi:10.1016/0002-9378(72)90774-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/4554554/pubmed" id="4554554" target="_blank">4554554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8023666">
<a name="8023666"></a>Louon A, Reddy VG. Nasal midazolam and ketamine for paediatric sedation during computerised tomography. <i>Acta Anaesthesiol Scand</i>. 1994;38(3):259-261. doi:10.1111/j.1399-6576.1994.tb03885.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8023666/pubmed" id="8023666" target="_blank">8023666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27648345">
<a name="27648345"></a>Loveday BA, Sindt J. Ketamine protocol for palliative care in cancer patients with refractory pain. <i>J Adv Pract Oncol</i>. 2015;6(6):555-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27648345/pubmed" id="27648345" target="_blank">27648345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17417623">
<a name="17417623"></a>Lyon F, Dabbs T, O'Meara M. Ketamine sedation during the treatment of retinopathy of prematurity. <i>Eye (Lond)</i>. 2008;22(5):684-686. doi:10.1038/sj.eye.6702717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17417623/pubmed" id="17417623" target="_blank">17417623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9272481">
<a name="9272481"></a>Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. <i>Neuropsychopharmacology</i>. 1997;17(3):141-150. doi:10.1016/S0893-133X(97)00036-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9272481/pubmed" id="9272481" target="_blank">9272481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8881626">
<a name="8881626"></a>Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. <i>Br J Anaesth</i>. 1996;77(2):203-207. doi:10.1093/bja/77.2.203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8881626/pubmed" id="8881626" target="_blank">8881626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25381898">
<a name="25381898"></a>Marchetti F, Coutaux A, Bellanger A, Magneux C, Bourgeois P, Mion G. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. <i>Eur J Pain</i>. 2015;19(7):984-993. doi:10.1002/ejp.624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25381898/pubmed" id="25381898" target="_blank">25381898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25010396">
<a name="25010396"></a>McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. <i>Psychol Med</i>. 2015;45(4):693-704. doi:10.1017/S0033291714001603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25010396/pubmed" id="25010396" target="_blank">25010396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15107365">
<a name="15107365"></a>McGlone RG, Howes MC, Joshi M. The Lancaster Experience of 2.0 to 2.5 mg/kg Intramuscular Ketamine for Paediatric Sedation: 501 Cases and Analysis. <i>Emerg Med J.</i> 2004;21(3):290-295. doi:10.1136/emj.2002.003772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15107365/pubmed" id="15107365" target="_blank">15107365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23413121">
<a name="23413121"></a>McPherson C. Sedation and analgesia in mechanically ventilated preterm neonates: continue standard of care or experiment? <i>J Pediatr Pharmacol Ther</i>. 2012;17(4):351-364. doi:10.5863/1551-6776-17.4.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23413121/pubmed" id="23413121" target="_blank">23413121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19404223">
<a name="19404223"></a>Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. <i>Pediatr Emerg Care</i>. 2009;25(5):325-328. doi:10.1097/PEC.0b013e3181a341e0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19404223/pubmed" id="19404223" target="_blank">19404223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17312200">
<a name="17312200"></a>Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. <i>Anesth Analg.</i> 2007;104(3):509-520. doi:10.1213/01.ane.0000255729.96438.b0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17312200/pubmed" id="17312200" target="_blank">17312200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11027905">
<a name="11027905"></a>Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. <i>J Pain Symptom Manage</i>. 2000;20(4):246-252. doi:10.1016/s0885-3924(00)00194-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/11027905/pubmed" id="11027905" target="_blank">11027905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29764182">
<a name="29764182"></a>Mercadante S, Caruselli A, Casuccio A. The use of ketamine in a palliative-supportive care unit: a retrospective analysis. <i>Ann Palliat Med</i>. 2018;7(2):205-210. doi:10.21037/apm.2018.01.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29764182/pubmed" id="29764182" target="_blank">29764182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31123547">
<a name="31123547"></a>Merelman AH, Perlmutter MC, Strayer RJ. Alternatives to rapid sequence intubation: contemporary airway management with ketamine. <i>West J Emerg Med</i>. 2019;20(3):466-471. doi:10.5811/westjem.2019.4.42753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31123547/pubmed" id="31123547" target="_blank">31123547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27130803">
<a name="27130803"></a>Miller M, Kruit N, Heldreich C, et al. Hemodynamic response after rapid sequence induction with ketamine in out-of-hospital patients at risk of shock as defined by the shock index. <i>Ann Emerg Med</i>. 2016;68(2):181-188.e2. doi:10.1016/j.annemergmed.2016.03.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27130803/pubmed" id="27130803" target="_blank">27130803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.2010">
<a name="Miller.2010"></a>Miller RD. <i>Miller’s Anesthesia.</i> 7th ed. Churchill Livingstone; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.1">
<a name="Moore.1"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10402883">
<a name="10402883"></a>Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. <i>Psychosomatics</i>. 1999;40(4):356-359. doi:10.1016/S0033-3182(99)71231-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10402883/pubmed" id="10402883" target="_blank">10402883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22840761">
<a name="22840761"></a>Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. <i>Biol Psychiatry</i>. 2013;74(4):250-256. doi:10.1016/j.biopsych.2012.06.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22840761/pubmed" id="22840761" target="_blank">22840761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16915900">
<a name="16915900"></a>Nagdeve NG, Yaddanapudi S, Pandav SS. The effect of different doses of ketamine on intraocular pressure in anesthetized children. <i>J Pediatr Ophthalmol Strabismus</i>. 2006;43(4):219-223. doi:10.3928/01913913-20060701-03<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/16915900/pubmed" id="16915900" target="_blank">16915900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28335913">
<a name="28335913"></a>Nazarian DJ, Broder JS, Thiessen MEW, Wilson MP, Zun LS, Brown MD; American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on the Adult Psychiatric Patient. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. <i>Ann Emerg Med</i>. 2017;69(4):480-498. doi:10.1016/j.annemergmed.2017.01.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28335913/pubmed" id="28335913" target="_blank">28335913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23470068">
<a name="23470068"></a>Neuman G, Koren G. Safety of procedural sedation in pregnancy. <i>J Obstet Gynaecol Can</i>. 2013;35(2):168-173. doi:10.1016/S1701-2163(15)31023-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23470068/pubmed" id="23470068" target="_blank">23470068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26423481">
<a name="26423481"></a>Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. <i>Am J Psychiatry</i>. 2015;172(10):950-966. doi:10.1176/appi.ajp.2015.15040465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26423481/pubmed" id="26423481" target="_blank">26423481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24118506">
<a name="24118506"></a>Nielsen BN, Friis SM, Rømsing J, et al. Intranasal sufentanil/ketamine analgesia in children. <i>Paediatr Anaesth</i>. 2014;24(2):170-180. doi:10.1111/pan.12268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24118506/pubmed" id="24118506" target="_blank">24118506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Niesters.2013">
<a name="Niesters.2013"></a>Niesters M, Martini C, Dahan A. Ketamine for chronic pain: Risks and benefits. <i>Br J Clin Pharmacology</i>. 2013;77(2):357-367. doi:10.1111/bcp.12094</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23480923">
<a name="23480923"></a>Norambuena C, Yañez J, Flores V, Puentes P, Carrasco P, Villena R. Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study. <i>J Pediatr Surg</i>. 2013;48(3):629-634. doi:10.1016/j.jpedsurg.2012.08.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23480923/pubmed" id="23480923" target="_blank">23480923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31335216">
<a name="31335216"></a>O'Brien ME, Fuh L, Raja AS, White BA, Yun BJ, Hayes BD. Reduced-dose intramuscular ketamine for severe agitation in an academic emergency department. <i>Clin Toxicol (Phila)</i>. 2020;58(4):294-298. doi:10.1080/15563650.2019.1643468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31335216/pubmed" id="31335216" target="_blank">31335216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30993550">
<a name="30993550"></a>Oddo M, Bracard S, Cariou A, et al. Update in neurocritical care: a summary of the 2018 Paris international conference of the French Society of Intensive Care. <i>Ann Intensive Care</i>. 2019;9(1):47. doi:10.1186/s13613-019-0523-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30993550/pubmed" id="30993550" target="_blank">30993550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17525784">
<a name="17525784"></a>Okon T. Ketamine: an introduction for the pain and palliative medicine physician. <i>Pain Physician</i>. 2007;10(3):493-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17525784/pubmed" id="17525784" target="_blank">17525784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32739857">
<a name="32739857"></a>Oliveira J E Silva L, Lee JY, Bellolio F, Homme JL, Anderson JL. Intranasal ketamine for acute pain management in children: A systematic review and meta-analysis. <i>Am J Emerg Med</i>. 2020;38(9):1860-1866. doi:10.1016/j.ajem.2020.05.094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/32739857/pubmed" id="32739857" target="_blank">32739857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888583">
<a name="28888583"></a>Olutoye OA, Baker BW, Belfort MA, Olutoye OO. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. <i>Am J Obstet Gynecol</i>. 2018;218(1):98-102. doi:10.1016/j.ajog.2017.08.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28888583/pubmed" id="28888583" target="_blank">28888583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31082965">
<a name="31082965"></a>Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. <i>Anesth Analg.</i> 2019;129(1):241-254. doi:10.1213/ANE.0000000000004185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31082965/pubmed" id="31082965" target="_blank">31082965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15357562">
<a name="15357562"></a>Ozdemir D, Kayserili E, Arslanoglu S, Gulez P, Vergin C. Ketamine and midazolam for invasive procedures in children with malignancy: a comparison of routes of intravenous, oral, and rectal administration. <i>J Trop Pediatr</i>. 2004;50(4):224-228. doi:10.1093/tropej/50.4.224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15357562/pubmed" id="15357562" target="_blank">15357562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2007">
<a name="Pai.2007"></a>Pai A, Heining M. Ketamine. Continuing education in anaesthesia, critical care and pain. <i>Br J Anaesthesia</i>. 2007;7(2):59-63. Accessed December 2021. https://academic.oup.com/bjaed/article/7/2/59/384361.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12075653">
<a name="12075653"></a>Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. <i>Anaesth Intensive Care</i>. 2002;30(3):382-384. doi:10.1177/0310057X0203000323<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12075653/pubmed" id="12075653" target="_blank">12075653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23474358">
<a name="23474358"></a>Pal R, Balt S, Erowid E, et al. Ketamine is associated with lower urinary tract signs and symptoms. <i>Drug Alcohol Depend</i>. 2013;132(1-2):189-194. doi:10.1016/j.drugalcdep.2013.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23474358/pubmed" id="23474358" target="_blank">23474358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19276968">
<a name="19276968"></a>Patel P, Sun L. Update on neonatal anesthetic neurotoxicity: insight into molecular mechanisms and relevance to humans. <i>Anesthesiology</i>. 2009;110(4):703-708. doi:10.1097/ALN.0b013e31819c42a4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19276968/pubmed" id="19276968" target="_blank">19276968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14627307">
<a name="14627307"></a>Pees C, Haas NA, Ewert P, Berger F, Lange PE. Comparison of analgesic/sedative effect of racemic ketamine and S(+)-ketamine during cardiac catheterization in newborns and children. <i>Pediatr Cardiol</i>. 2003;24(5):424-429. doi:10.1007/s00246-002-0356-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/14627307/pubmed" id="14627307" target="_blank">14627307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24807773">
<a name="24807773"></a>Peng TR, Lee MC, Wu TW, Lan CC. Suspected ketamine-associated lower urinary tract symptoms. <i>Urol J</i>. 2014;11(2):1508-1510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24807773/pubmed" id="24807773" target="_blank">24807773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31759333">
<a name="31759333"></a>Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. <i>Neuropsychopharmacology</i>. 2020;45(4):606-612. doi:10.1038/s41386-019-0570-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31759333/pubmed" id="31759333" target="_blank">31759333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30922101">
<a name="30922101"></a>Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. <i>Am J Psychiatry</i>. 2019;176(5):401-409. doi:10.1176/appi.ajp.2018.18070834<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30922101/pubmed" id="30922101" target="_blank">30922101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28319161">
<a name="28319161"></a>Poonai N, Canton K, Ali S, et al. Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. <i>PLoS One</i>. 2017;12(3):e0173253. doi:10.1371/journal.pone.0173253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28319161/pubmed" id="28319161" target="_blank">28319161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26361209">
<a name="26361209"></a>Powers AR 3rd, Gancsos MG, Finn ES, Morgan PT, Corlett PR. Ketamine-induced hallucinations. <i>Psychopathology</i>. 2015;48(6):376-385. doi:10.1159/000438675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26361209/pubmed" id="26361209" target="_blank">26361209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096492">
<a name="26096492"></a>Quibell R, Fallon M, Mihalyo M, Twycross R, Wilcock A. Ketamine. <i>J Pain Symptom Manage</i>. 2015;50(2):268-278. doi:10.1016/j.jpainsymman.2015.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26096492/pubmed" id="26096492" target="_blank">26096492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21419322">
<a name="21419322"></a>Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A. Ketamine*. <i>J Pain Symptom Manage</i>. 2011;41(3):640-649. doi:10.1016/j.jpainsymman.2011.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21419322/pubmed" id="21419322" target="_blank">21419322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29922905">
<a name="29922905"></a>Rai S, Drislane FW. Treatment of refractory and super-refractory status epilepticus. <i>Neurotherapeutics</i>. 2018;15(3):697-712. doi:10.1007/s13311-018-0640-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29922905/pubmed" id="29922905" target="_blank">29922905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23428794">
<a name="23428794"></a>Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. <i>J Psychopharmacol</i>. 2013;27(5):444-450. doi:10.1177/0269881113478283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23428794/pubmed" id="23428794" target="_blank">23428794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28366351">
<a name="28366351"></a>Rech MA, Barbas B, Chaney W, Greenhalgh E, Turck C. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. <i>Ann Emerg Med</i>. 2017;70(2):203-211. doi:10.1016/j.annemergmed.2017.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28366351/pubmed" id="28366351" target="_blank">28366351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28926159">
<a name="28926159"></a>Reynolds SL, Bryant KK, Studnek JR, et al. Randomized controlled feasibility trial of intranasal ketamine compared to intranasal fentanyl for analgesia in children with suspected extremity fractures. <i>Acad Emerg Med</i>. 2017;24(12):1430-1440. doi:10.1111/acem.13313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28926159/pubmed" id="28926159" target="_blank">28926159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28237385">
<a name="28237385"></a>Riddell J, Tran A, Bengiamin R, Hendey GW, Armenian P. Ketamine as a first-line treatment for severely agitated emergency department patients. <i>Am J Emerg Med</i>. 2017;35(7):1000-1004. doi:10.1016/j.ajem.2017.02.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28237385/pubmed" id="28237385" target="_blank">28237385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.2019">
<a name="Roberts.2019"></a>Roberts JR, Custalow CB, Thomsenet TW, et al, eds. <i>Roberts and Hedges' Clinical Procedures in Emergency Medicine and Acute Care</i>. 7th ed. Elsevier. 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3698618">
<a name="3698618"></a>Rock MJ, Reyes de la Rocha S, L'Hommedieu CS, Truemper E. Use of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapy. <i>Crit Care Med</i>. 1986;14(5):514-516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/3698618/pubmed" id="3698618" target="_blank">3698618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675259">
<a name="15675259"></a>Roelofse JA, Shipton EA, de la Harpe CJ, Blignaut RJ. Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison. <i>Anesth Prog</i>. 2004;51(4):114-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15675259/pubmed" id="15675259" target="_blank">15675259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30232735">
<a name="30232735"></a>Rosati A, De Masi S, Guerrini R. Ketamine for refractory status epilepticus: a systematic review. <i>CNS Drugs</i>. 2018;32(11):997-1009. doi:10.1007/s40263-018-0569-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30232735/pubmed" id="30232735" target="_blank">30232735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28249076">
<a name="28249076"></a>Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. <i>JAMA Psychiatry</i>. 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/28249076/pubmed" id="28249076" target="_blank">28249076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schumann.1">
<a name="Schumann.1"></a>Schumann R. Anesthesia for the obese patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed July 29, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29870457">
<a name="29870457"></a>Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. <i>Reg Anesth Pain Med</i>. 2018;43(5):456-466. doi:10.1097/AAP.0000000000000806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29870457/pubmed" id="29870457" target="_blank">29870457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20947210">
<a name="20947210"></a>Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M, Rieder M. A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children.<i> Ann Emerg Med</i>. 2011;57(5):425-433.e2. doi:10.1016/j.annemergmed.2010.08.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20947210/pubmed" id="20947210" target="_blank">20947210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27829367">
<a name="27829367"></a>Shimonovich S, Gigi R, Shapira A, et al. Intranasal ketamine for acute traumatic pain in the emergency department: a prospective, randomized clinical trial of efficacy and safety. <i>BMC Emerg Med.</i> 2016;16(1):43. doi:10.1186/s12873-016-0107-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27829367/pubmed" id="27829367" target="_blank">27829367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24268616">
<a name="24268616"></a>Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. <i>J Affect Disord</i>. 2014;155:123-129. doi:10.1016/j.jad.2013.10.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24268616/pubmed" id="24268616" target="_blank">24268616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27006733">
<a name="27006733"></a>Shrestha R, Pant S, Shrestha A, Batajoo KH, Thapa R, Vaidya S. Intranasal ketamine for the treatment of patients with acute pain in the emergency department. <i>World J Emerg Med</i>. 2016;7(1):19-24. doi:10.5847/wjem.j.1920-8642.2016.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27006733/pubmed" id="27006733" target="_blank">27006733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27056608">
<a name="27056608"></a>Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. <i>Am J Psychiatry</i>. 2016;173(8):816-826. doi:10.1176/appi.ajp.2016.16010037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27056608/pubmed" id="27056608" target="_blank">27056608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29396996">
<a name="29396996"></a>Singh V, Gillespie TW, Harvey RD. Intranasal ketamine and its potential role in cancer-related pain. <i>Pharmacotherapy</i>. 2018;38(3):390-401. doi:10.1002/phar.2090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29396996/pubmed" id="29396996" target="_blank">29396996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21803784">
<a name="21803784"></a>Soto E, Stewart DR, Mannes AJ, et al. Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome. <i>Am J Hosp Palliat Care</i>. 2012;29(4): 308–317. doi:10.1177/1049909111416345<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21803784/pubmed" id="21803784" target="_blank">21803784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SPS.1">
<a name="SPS.1"></a>Society for Pediatric Sedation (SPS). FDA advisory on anesthesia and sedation medication in children. Society for Pediatric Sedation website. https://www.pedsedation.org/resources/quality-safety/fda-advisory/#:~:text=In%20December%202016%2C%20the%20FDA,(http%3A%2F%2Fwww.fda. Accessed April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259635">
<a name="24259635"></a>Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. <i>Ann Pharmacother</i>. 2014;48(1):62-76. doi:10.1177/1060028013510488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24259635/pubmed" id="24259635" target="_blank">24259635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18544145">
<a name="18544145"></a>Sungur Ulke Z, Kartal U, Orhan Sungur M, Camci E, Tugrul M. Comparison of sevoflurane and ketamine for anesthetic induction in children with congenital heart disease. <i>Paediatr Anaesth</i>. 2008;18(8):715-21. doi:10.1111/j.1460-9592.2008.02637.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18544145/pubmed" id="18544145" target="_blank">18544145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25095322">
<a name="25095322"></a>Surendar MN, Pandey RK, Saksena AK, Kumar R, Chandra G. A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. <i>J Clin Pediatr Dent</i>. 2014;38(3):255-261. doi:10.17796/jcpd.38.3.l828585807482966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25095322/pubmed" id="25095322" target="_blank">25095322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33174760">
<a name="33174760"></a>Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. <i>Can J Psychiatry</i>. 2021;66(2):113-125. doi:10.1177/0706743720970860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33174760/pubmed" id="33174760" target="_blank">33174760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31488795">
<a name="31488795"></a>Szarmach J, Cubała WJ, Włodarczyk A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. <i>Psychiatr Danub</i>. 2019;31(suppl 3):585-590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31488795/pubmed" id="31488795" target="_blank">31488795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30498609">
<a name="30498609"></a>Talahma M, Sabharwal V, Bukovskaya Y, Khan F. Ketamine infusion used to successfully control refractory status epilepticus in a pregnant patient. <i>Case Rep Neurol Med</i>. 2018;2018:3041279. doi:10.1155/2018/3041279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30498609/pubmed" id="30498609" target="_blank">30498609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11046209">
<a name="11046209"></a>Tanaka M, Sato M, Saito A, Nishikawa T. Reevaluation of rectal ketamine premedication in children: comparison with rectal midazolam. <i>Anesthesiology</i>. 2000;93(5):1217-1224. doi:10.1097/00000542-200011000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/11046209/pubmed" id="11046209" target="_blank">11046209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23856095">
<a name="23856095"></a>Tawfic QA, Faris AS, Kausalya R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. <i>J Pain Symptom Manage</i>. 2014;47(2):334-340. doi:10.1016/j.jpainsymman.2013.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23856095/pubmed" id="23856095" target="_blank">23856095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thase.1">
<a name="Thase.1"></a>Thase M, Connolly KR. Ketamine and esketamine for treating unipolar depression in adults: administration, efficacy, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed March 5, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2379394">
<a name="2379394"></a>Tobias JD, Martin LD, Wetzel RC. Ketamine by continuous infusion for sedation in the pediatric intensive care unit. <i>Crit Care Med</i>. 1990;18(8):819-821. doi:10.1097/00003246-199008000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2379394/pubmed" id="2379394" target="_blank">2379394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1408506">
<a name="1408506"></a>Tobias JD, Phipps S, Smith B, Mulhern RK. Oral ketamine premedication to alleviate the distress of invasive procedures in pediatric oncology patients. <i>Pediatrics</i>. 1992;90(4):537-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1408506/pubmed" id="1408506" target="_blank">1408506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7984386">
<a name="7984386"></a>Tobias JD, Rasmussen GE. Pain management and sedation in the pediatric intensive care unit. <i>Pediatr Clin North Am.</i> 1994;41(6):1269-1292. doi:10.1016/s0031-3955(16)38873-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7984386/pubmed" id="7984386" target="_blank">7984386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15385013">
<a name="15385013"></a>Tomatir E, Atalay H, Gurses E, Erbay H, Bozkurt P. Effects of low dose ketamine before induction on propofol anesthesia for pediatric magnetic resonance imaging. <i>Paediatr Anaesth</i>. 2004;14(10):845-850. doi:10.1111/j.1460-9592.2004.01303.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15385013/pubmed" id="15385013" target="_blank">15385013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12553389">
<a name="12553389"></a>Turhanoğlu S, Kararmaz A, Ozyilmaz MA, Kaya S, Tok D. Effects of different doses of oral ketamine for premedication of children. <i>Eur J Anaesthesiol</i>. 2003;20(1):56-60. doi:10.1017/s0265021503000103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12553389/pubmed" id="12553389" target="_blank">12553389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993308">
<a name="27993308"></a>Upchurch CP, Grijalva CG, Russ S, et al. Comparison of etomidate and ketamine for induction during rapid sequence intubation of adult trauma patients. <i>Ann Emerg Med.</i> 2017;69(1):24-33.e2. doi:10.1016/j.annemergmed.2016.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27993308/pubmed" id="27993308" target="_blank">27993308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.2020">
<a name="VADoD.2020"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the assessment and management of patients as risk for suicide. Updated May 2019. Accessed March 24, 2020. <a href="https://www.healthquality.va.gov/guidelines/MH/srb/VADoDSuicideRiskFullCPGFinal5088919.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/srb/VADoDSuicideRiskFullCPGFinal5088919.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.1">
<a name="VADoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Updated February 2022. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27625475">
<a name="27625475"></a>Vadivelu N, Schermer E, Kodumudi V, Belani K, Urman RD, Kaye AD. Role of ketamine for analgesia in adults and children. <i>J Anaesthesiol Clin Pharmacol.</i> 2016;32(3):298-306. doi:10.4103/0970-9185.168149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27625475/pubmed" id="27625475" target="_blank">27625475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1890517">
<a name="1890517"></a>van der Bijl P, Roelofse JA, Stander IA. Rectal ketamine and midazolam for premedication in pediatric dentistry.<i> J Oral Maxillofac Surg</i>. 1991;49(10):1050-1054. doi:10.1016/0278-2391(91)90136-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1890517/pubmed" id="1890517" target="_blank">1890517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9435992">
<a name="9435992"></a>Wagner BK, O'Hara DA. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. <i>Clin Pharmacokinet</i>. 1997;33(6):426-453. doi:10.2165/00003088-199733060-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9435992/pubmed" id="9435992" target="_blank">9435992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30095550">
<a name="30095550"></a>Wang J, Echevarria GC, Doan L, et al. Effects of a single subanaesthetic dose of ketamine on pain and mood after laparoscopic bariatric surgery: a randomised double-blind placebo controlled study. <i>Eur J Anaesthesiol</i>. 2019;36(1):16-24. doi:10.1097/EJA.0000000000000860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/30095550/pubmed" id="30095550" target="_blank">30095550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20865876">
<a name="20865876"></a>Wang X, Zhou ZJ, Zhang XF, Zheng S. A comparison of two different doses of rectal ketamine added to 0.5 mg x kg(-1) midazolam and 0.02 mg x kg(-1) atropine in infants and young children. <i>Anaesth Intensive Care</i>. 2010;38(5):900-904. doi:10.1177/0310057X1003800515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20865876/pubmed" id="20865876" target="_blank">20865876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23832948">
<a name="23832948"></a>Wei YB, Yang JR, Yin Z, Guo Q, Liang BL, Zhou KQ. Genitourinary toxicity of ketamine. <i>Hong Kong Med J</i>. 2013;19(4):341-348. doi:10.12809/hkmj134013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23832948/pubmed" id="23832948" target="_blank">23832948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8443849">
<a name="8443849"></a>Weksler N, Ovadia L, Muati G, Stav A. Nasal ketamine for paediatric premedication. <i>Can J Anaesth</i>. 1993;40(2):119-121. doi:10.1007/BF03011307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8443849/pubmed" id="8443849" target="_blank">8443849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6892475">
<a name="6892475"></a>White PF, Way WL, Trevor AJ. Ketamine − its pharmacology and therapeutic uses. <i>Anesthesiology.</i> 1982;56(2):119-136. doi:10.1097/00000542-198202000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/6892475/pubmed" id="6892475" target="_blank">6892475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17059854">
<a name="17059854"></a>Willman EV, Andolfatto G. A prospective evaluation of "ketofol" (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2007;49(1):23-30. doi:10.1016/j.annemergmed.2006.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17059854/pubmed" id="17059854" target="_blank">17059854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729893">
<a name="31729893"></a>Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. <i>Aust N Z J Psychiatry</i>. 2020;54(1):29-45. doi:10.1177/0004867419883341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/31729893/pubmed" id="31729893" target="_blank">31729893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803768">
<a name="24803768"></a>Wu L, Lalwani K, Hook KA, Almario BM, Fu R, Edmunds B. Respiratory complications associated with ketamine anesthesia for ophthalmic procedures following intraocular pressure measurement in children. <i>J Anaesthesiol Clin Pharmacol</i>. 2014;30(2):253-257. doi:10.4103/0970-9185.130047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24803768/pubmed" id="24803768" target="_blank">24803768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33360864">
<a name="33360864"></a>Xiong J, Lipsitz O, Chen-Li D, et al. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. <i>J Psychiatr Res</i>. 2021;134:57-68. doi:10.1016/j.jpsychires.2020.12.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/33360864/pubmed" id="33360864" target="_blank">33360864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24659739">
<a name="24659739"></a>Yan J, Li YR, Zhang Y, Lu Y, Jiang H. Repeated exposure to anesthetic ketamine can negatively impact neurodevelopment in infants: a prospective preliminary clinical study. <i>J Child Neurol</i>. 2014;29(10):1333-1338. doi:10.1177/0883073813517508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24659739/pubmed" id="24659739" target="_blank">24659739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24712757">
<a name="24712757"></a>Yeaman F, Meek R, Egerton-Warburton D, Rosengarten P, Graudins A. Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. <i>Emerg Med Australas</i>. 2014;26(3):237-242. doi:10.1111/1742-6723.12173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24712757/pubmed" id="24712757" target="_blank">24712757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29287863">
<a name="29287863"></a>Yenigun A, Yilmaz S, Dogan R, Goktas SS, Calim M, Ozturan O. Demonstration of analgesic effect of intranasal ketamine and intranasal fentanyl for postoperative pain after pediatric tonsillectomy. <i>Int J Pediatr Otorhinolaryngol</i>. 2018;104:182-185. doi:10.1016/j.ijporl.2017.11.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/29287863/pubmed" id="29287863" target="_blank">29287863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8905436">
<a name="8905436"></a>Youssef-Ahmed MZ, Silver P, Nimkoff L, Sagy M. Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm. <i>Intensive Care Med</i>. 1996;22(9):972-976. doi:10.1007/BF02044126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8905436/pubmed" id="8905436" target="_blank">8905436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36042988">
<a name="36042988"></a>Zaki HA, Shallik N, Shaban E, et al. An analytical comparison between ketamine alone and a combination of ketamine and propofol (Ketofol) for procedural sedation and analgesia from an emergency perspective: a systematic review and meta-analysis. <i>Cureus</i>. 2022;14(7):e27318. doi:10.7759/cureus.27318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/36042988/pubmed" id="36042988" target="_blank">36042988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20157833">
<a name="20157833"></a>Zanette G, Micaglio M, Zanette L, Manani G, Facco E. Comparison between ketamine and fentanyl-droperidol for rectal premedication in children: a randomized placebo controlled trial. <i>J Anesth</i>. 2010;24(2):197-203. doi:10.1007/s00540-010-0884-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20157833/pubmed" id="20157833" target="_blank">20157833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24515638">
<a name="24515638"></a>Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. <i>Neurocrit Care</i>. 2014;21(1):163-173. doi:10.1007/s12028-013-9950-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24515638/pubmed" id="24515638" target="_blank">24515638</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8588 Version 447.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
